Anti-tetranor-PGDM monoclonal antibody and its uses

Monoclonal antibodies specific to tetranor-PGDM, developed through enzyme immunoassays, address the limitations of current diagnostic methods by providing accurate and safe detection for food allergies.

JP7595328B2Active Publication Date: 2024-12-06THE UNIV OF TOKYO +1
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2023500955
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2021-02-22
Filing Date
2022-02-21
Publication Date
2024-12-06
Estimated Expiration
2042-02-21

AI Technical Summary

Technical Problem

Current diagnostic methods for food allergies, such as measuring IgE antibodies and oral antigen challenge tests, are not accurate or safe, and existing monoclonal antibodies for tetranor-PGDM are not specific enough for reliable detection, leading to difficulties in diagnosing and treating food allergies.

Method used

Development of monoclonal antibodies specific to tetranor-PGDM, which are created by immunizing mice lacking the enzyme to produce tetranor-PGDM, and characterized by specific CDR sequences, allowing for the use of enzyme immunoassays for detection.

Benefits of technology

Enables easy and accurate detection of tetranor-PGDM in body fluids, facilitating diagnosis and monitoring of food allergies and other diseases, with high specificity and sensitivity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007595328000008
    Figure 0007595328000008
  • Figure 0007595328000009
    Figure 0007595328000009
  • Figure 0007595328000010
    Figure 0007595328000010
Patent Text Reader

Abstract

The present invention provides a monoclonal antibody capable of binding to tetranor-PGDM specifically or a fragment of the monoclonal antibody.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention broadly relates to a monoclonal antibody or a fragment thereof that targets tetranor-PGDM, and uses thereof. [Background technology]

[0002] Food allergies are a disease that can cause symptoms such as hives, diarrhea, and vomiting in response to ingested foods, as well as anaphylaxis, which can be fatal. The number of patients with this disease, which is common among children, is increasing rapidly, and the severity of the condition is also becoming a serious problem.

[0003] Measuring the concentration of IgE antibodies in the blood is widely used as a method for testing allergies, but this test does not tell us whether symptoms will appear when a food is eaten. Therefore, the only way to diagnose food allergies is to perform an "oral antigen challenge test." However, this takes a lot of time and effort, and there is a risk of anaphylaxis. In addition, "oral immunotherapy" is one way to treat food allergies, but it requires continuing to eat small amounts of antigens that do not cause symptoms for several years, which also carries the risk of accidents. Thus, the lack of simple and accurate diagnostic methods and symptom evaluation methods is a bottleneck in the development of diagnostic and treatment methods for food allergies, which are increasing in number.

[0004] The present inventors have discovered that tetranor-PGDM (9α-hydroxy-11,15-dioxo-13,14-dihydro-2,3,4,5-tetranor-prostan-1,20-dioic acid), a metabolic product of lipid prostaglandin (PG) D2, is excreted in urine, which is easy to collect even from children, in a manner specific to food allergies and proportional to the severity of symptoms (Patent Document 1). However, measurement of this concentration requires the use of a mass spectrometer, which is difficult to operate and expensive. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] International Publication No. 2016 / 021704 [Patent Document 2] US Patent Application Publication No. 2012 / 0021437 Summary of the Invention [Problem to be solved by the invention]

[0006] Although polyclonal antibodies against tetranor-PGDM are known (https: / / www.caymanchem.com / product / 501001 / tetranor-pgdm-elisa-kit; US Patent Application Publication No. 2012 / 0021437 (Patent Document 2)), polyclonal antibodies are inferior to monoclonal antibodies in terms of specificity, manufacturing stability, and measurement reproducibility. In addition to these quality issues, polyclonal antibodies cannot be applied to test for human diseases because of the difference in performance between lots.

[0007] Therefore, there was a desire to develop a monoclonal antibody against tetranor-PGDM, but tetranor-PGDM has a small molecular weight as an antigen, making it difficult for antibodies to recognize it, and it is also present in the body, making it difficult to develop a monoclonal antibody against tetranor-PGDM. [Means for solving the problem]

[0008] The inventors succeeded in producing a monoclonal antibody specific to tetranor-PGDM for the first time by immunizing a complex of tetranor-PGDM and keyhole limpet hemocyanin (KLH) into mice that are deficient in the genes encoding two types of PGD2 synthesis enzymes, hematopoietic and lipocalin, and therefore do not produce PGD2 or its metabolic product, tetranor-PGDM.

[0009] In addition, Patent Document 2 describes a method for producing a monoclonal antibody against tetranor-PGDM by injecting a complex of tetranor-PGDM and keyhole limpet hemocyanin (KLH) into a wild-type mouse, but does not provide any specific description of the obtained antibody. When the present inventor similarly immunized a wild-type mouse, no monoclonal antibody specific to tetranor-PGDM was obtained.

[0010] In addition, Patent Document 2 shows cross-reactivity of an antibody against tetranor-PGDM, which is thought to be a polyclonal antibody (paragraph 0347), but it binds not only to tetranor-PGDM but also to tetranor-PGEM (Tetranor-PGJM 376%; Tetranor-PGDM 100%; Tetranor-PGEM 0.3%), which is different from the monoclonal antibody of the present invention that does not substantially bind to tetranor-PGEM (e.g., Tetranor-PGJM 563%; Tetranor-PGDM 100%; Tetranor-PGEM 0.00%). Both have in common the fact that they bind to tetranor-PGJM, but tetranor-PGJM is hardly produced in the body and is not excreted in urine. On the other hand, tetranor-PGEM is produced in large quantities in the body and is detected in urine, so whether or not it binds to tetranor-PGEM is an extremely important difference. Such a difference is thought to be due to, for example, a difference in CDR.

[0011] That is, the present invention includes the following inventions. [1] A monoclonal antibody or a fragment thereof that specifically binds to tetranor-PGDM. [2] The monoclonal antibody or fragment thereof according to [1], which does not substantially bind to tetranor-PGEM, tetranor-PGFM, or tetranor-PGAM. [3] The monoclonal antibody or fragment thereof according to [1] or [2], which recognizes the carbon chain at positions 7 to 11 of tetranor-PGDM. [4] below: (a) a CDRH1 consisting of the amino acid sequence set forth in GYT-Xaa1-T-Xaa2-Y-Xaa3 (SEQ ID NO: 1), where Xaa1 is F, A or S, Xaa2 is N or R, and Xaa3 is A or W; (b) a CDRH2 consisting of the amino acid sequence set forth in I-Xaa4-P-Xaa5-Xaa6-Xaa7-Xaa8-T (SEQ ID NO: 2), where Xaa4 is N or Y, Xaa5 is F or G, Xaa6 is N or D, Xaa7 is D or G, and Xaa8 is G, N, or D; (c) a CDRH3 consisting of the amino acid sequence set forth in A-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-Xaa17-Xaa18-Xaa19-Xaa20 (SEQ ID NO: 3), in which Xaa9 is R, S or T, Xaa10 is Y or V, Xaa11 is Y or absent, Xaa12 is Y or absent, Xaa13 is Y or absent, Xaa14 is G or S, Xaa15 is S or R, Xaa16 is K or W, Xaa17 is A or F, Xaa18 is M or F, Xaa19 is D or A, and Xaa20 is Y or V; (d) a CDRL1 consisting of the amino acid sequence set forth in Xaa21-GAV-Xaa22-Xaa23-S-Xaa24-Xaa25 (SEQ ID NO: 4), in which Xaa21 is T or S, Xaa22 is T or R, Xaa23 is T or I, Xaa24 is N, Y or K, and Xaa25 is Y or H; (e) a CDRL2 consisting of the amino acid sequence set forth in Xaa26-T-Xaa27, where Xaa26 is G or D and Xaa27 is N or D; and (f) a CDRL3 consisting of the amino acid sequence set forth in SEQ ID NO:5: ALW-Xaa28-SNHW-Xaa29, wherein Xaa28 is Y, F or N, and Xaa29 is V or I; or comprising at least one CDR selected from the group consisting of At least one CDR having an amino acid sequence in which one or several amino acids are deleted, substituted or added in the amino acid sequence of each CDR; or A monoclonal antibody or a fragment thereof according to any one of [1] to [3], comprising at least one CDR having an amino acid sequence having 80% or more identity with the amino acid sequence of each CDR. [5] The monoclonal antibody or fragment thereof according to [4], wherein in CDRH1 (a), when Xaa2 is N, Xaa1 is F and Xaa3 is A; or when Xaa2 is R, Xaa1 is F, A or S. [6] A monoclonal antibody or fragment thereof according to [4] or [5], wherein in CDRH2 of (b), when Xaa4 is N, Xaa5 is F, Xaa6 is N, Xaa7 is D, and Xaa8 is G; or when Xaa4 is Y, Xaa5 is G, Xaa6 is D, Xaa7 is G, and Xaa8 is N or D. [7] The monoclonal antibody or fragment thereof according to any of [4] to [6], wherein in CDRH3 of (c), when Xaa10 is Y, Xaa9 is R, Xaa11 is Y, Xaa12 is Y, Xaa13 is Y, Xaa14 is G, Xaa15 is S, Xaa16 is K, Xaa17 is A, Xaa18 is M, Xaa19 is D, and Xaa20 is Y; or when Xaa10 is V, Xaa9 is S or T, Xaa11 is absent, Xaa12 is absent, Xaa13 is absent, Xaa14 is S, Xaa15 is R, Xaa16 is W, Xaa17 is F, Xaa18 is F, Xaa19 is A, and Xaa20 is V. [8] The monoclonal antibody or fragment thereof according to any of [4] to [7], wherein in CDRL1 of (d), when Xaa22 and Xaa23 are each T, Xaa21 is T or S, Xaa24 is N, Y or K, and Xaa25 is Y or H; or when Xaa22 is R and Xaa23 is I, Xaa21 is T, Xaa24 is N, and Xaa25 is Y. [9] The monoclonal antibody or fragment thereof according to any one of [4] to [8], wherein in CDRL2 of (e), when Xaa26 is G, Xaa27 is not D.

[10] The monoclonal antibody or fragment thereof according to any of [4] to [9], wherein in CDRL3 (f), when Xaa28 is Y, Xaa29 is V or I; when Xaa28 is F, Xaa29 is V; or when Xaa28 is N, Xaa29 is V.

[11] The monoclonal antibody or fragment thereof according to any one of [1] to

[10] , wherein the constant region is derived from human.

[12] The monoclonal antibody or fragment thereof according to any one of [1] to

[11] , which is human chimeric or humanized.

[13] The monoclonal antibody or fragment thereof according to any one of [1] to

[12] , which is selected from the group consisting of Fab, F(ab')2, Fab', Fv and single-chain antibodies.

[14] A polynucleotide encoding the monoclonal antibody or a fragment thereof according to any one of [1] to

[13] .

[15] An expression vector comprising the polynucleotide described in

[14] .

[16] A host cell transfected with the expression vector described in

[15] .

[17] A host cell described in

[16] , which is a eukaryotic cell.

[18] A hybridoma that produces the monoclonal antibody according to any one of [1] to

[13] .

[19] A diagnostic agent for a tetranor-PGDM-related disease, comprising the monoclonal antibody or a fragment thereof according to any one of [1] to

[13] .

[20] The diagnostic agent according to

[19] , wherein the tetranor-PGDM-related disease is food allergy, anaphylactic reaction, muscular dystrophy, or aspirin-intolerant asthma. [twenty one] A kit comprising the monoclonal antibody or a fragment thereof according to any one of [1] to

[13] , or the diagnostic agent according to

[19] or

[20] . [twenty two] The kit described in

[21] further comprises a solid phase carrier, on which the monoclonal antibody or a fragment thereof is immobilized. [twenty three] A method for detecting tetranor-PGDM using a monoclonal antibody or a fragment thereof described in any one of [1] to

[13] , or a diagnostic agent described in

[19] or

[20] . [twenty four] 1. A method for assisting a subject in determining whether or not they have a food allergy, comprising: detecting the amount of tetranor-PGDM in urine using the monoclonal antibody or fragment thereof according to any one of [1] to

[13] , or the diagnostic agent according to

[19] or

[20] ; A method comprising a step of assisting in determining that the higher the amount of tetranor-PGDM in the urine, the more severe or has become the symptoms of food allergy, or the higher or has become the risk of developing a food allergy. [twenty five] The method according to

[24] , further comprising a step of measuring the amount of tetranor-PGEM in urine. Effect of the Invention

[0012] The anti-tetranor-PGDM monoclonal antibody of the present invention makes it possible to easily detect tetranor-PGDM, which has conventionally been measured by mass spectrometry, by enzyme immunoassay etc. Such enzyme immunoassay methods are expected to be useful for quantifying tetranor-PGDM in body fluids, evaluating animal disease models, as a diagnostic indicator, and for monitoring the treatment of food allergies and other diseases. [Brief description of the drawings]

[0013] [Figure 1] Figure 1 shows the effects of pH (A) and ionic strength (B) on the performance of an enzyme immunoassay using an anti-tetranor-PGDM monoclonal antibody; the competition curve for tetranor-PGDM under optimized conditions (C) and the detection limit for tetranor-PGDM (D). [Diagram 2] Figure 2 shows the structures of tetranor-PGDM, tetranor-PGEM, tetranor-PGFM, and tetranor-PGAM. [Diagram 3] FIG. 3 shows the results of serially diluting and measuring tetranor-PGDM recovered from artificial urine before (A) and after (B) solid-phase extraction. [Figure 4] FIG. 4 shows the sequence of the 31-13 antibody H chain. [Diagram 5] FIG. 5 shows the sequence of the 31-13 antibody L chain. [Figure 6] FIG. 6 shows the sequence of the 44-63 antibody H chain. [Figure 7] FIG. 7 shows the sequence of the 44-63 antibody light chain. [Figure 8] FIG. 8 shows the sequence of the 47-11 antibody H chain. [Figure 9] FIG. 9 shows the sequence of the 47-11 antibody L chain. [Figure 10] FIG. 10 shows the sequence of the 50-32 antibody heavy chain. [Figure 11] FIG. 11 shows the sequence of the 50-32 antibody light chain. [Figure 12]FIG. 12 shows the sequence of the 53-113 antibody heavy chain. [Figure 13] FIG. 13 shows the sequence of the 53-113 antibody light chain. [Figure 14] FIG. 14 shows the sequence of the 60-141 antibody heavy chain. [Figure 15] FIG. 15 shows the sequence of the 60-141 antibody light chain. [Figure 16] FIG. 16 shows an alignment of the amino acid sequences of each antibody. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] (Anti-tetranor-PGDM monoclonal antibody) In a first aspect, a monoclonal antibody or a fragment thereof that specifically binds to tetranor-PGDM is provided. Hereinafter, this antibody is also simply referred to as an anti-tetranor-PGDM monoclonal antibody. As used herein, "specifically binds to tetranor-PGDM" means that the antibody does not substantially bind to tetranor-PGEM, tetranor-PGFM, or tetranor-PGAM, but specifically binds to tetranor-PGDM or tetranor-PGJM. A monoclonal antibody that does not bind to tetranor-PGEM is preferred because it is excreted in particularly large amounts in body fluids including urine. Note that tetranor-PGJM is hardly produced in the body and is not excreted in urine, so that an anti-tetranor-PGDM monoclonal antibody can be said to be a substantially tetranor-PGDM-specific antibody.

[0015] Anti-tetranor-PGDM monoclonal antibodies can be produced using hybridomas obtained by fusing antibody-producing cells with myelomas. The produced antibodies may be subjected to additional steps such as purification steps before recovery. For example, in order to increase the purity, it is preferable to carry out salting out, filtration through a filter, clarification using centrifugation, recovery by affinity, intermediate purification by ion exchange, and final purification by gel filtration.

[0016] Examples of anti-tetranor-PGDM monoclonal antibodies thus obtained include those having the following complementarity determining regions (CDRs): (a) a CDRH1 consisting of the amino acid sequence set forth in GYT-Xaa1-T-Xaa2-Y-Xaa3 (SEQ ID NO: 1), where Xaa1 is F, A or S, Xaa2 is N or R, and Xaa3 is A or W; (b) a CDRH2 consisting of the amino acid sequence set forth in I-Xaa4-P-Xaa5-Xaa6-Xaa7-Xaa8-T (SEQ ID NO: 2), where Xaa4 is N or Y, Xaa5 is F or G, Xaa6 is N or D, Xaa7 is D or G, and Xaa8 is G, N, or D; (c) a CDRH3 consisting of the amino acid sequence set forth in A-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-Xaa17-Xaa18-Xaa19-Xaa20 (SEQ ID NO: 3), in which Xaa9 is R, S or T, Xaa10 is Y or V, Xaa11 is Y or absent, Xaa12 is Y or absent, Xaa13 is Y or absent, Xaa14 is G or S, Xaa15 is S or R, Xaa16 is K or W, Xaa17 is A or F, Xaa18 is M or F, Xaa19 is D or A, and Xaa20 is Y or V; (d) a CDRL1 consisting of the amino acid sequence set forth in Xaa21-GAV-Xaa22-Xaa23-S-Xaa24-Xaa25 (SEQ ID NO: 4), in which Xaa21 is T or S, Xaa22 is T or R, Xaa23 is T or I, Xaa24 is N, Y or K, and Xaa25 is Y or H; (e) a CDRL2 consisting of the amino acid sequence set forth in Xaa26-T-Xaa27, where Xaa26 is G or D and Xaa27 is N or D; and (f) a CDRL3 consisting of the amino acid sequence set forth in SEQ ID NO:5: ALW-Xaa28-SNHW-Xaa29, wherein Xaa28 is Y, F or N, and Xaa29 is V or I; Examples of such antibodies include antibodies that contain at least one or more CDRs, preferably all six CDRs, selected from the group consisting of: (a) CDR 1, (b) CDR 2, and (c) CDR 3. Antibodies generally have a structure in which two heavy chains and two light chains are covalently bound by disulfide bonds, and each heavy chain is divided into a heavy chain variable region and a heavy chain constant region, and each light chain is divided into a light chain variable region and a light chain constant region. Each variable region contains three CDRs. Here, CDRH1, CDRH2, and CDRH3 are the heavy chain complementarity determining regions written in order from the amino terminal side of the heavy chain amino acid sequence, and CDRL1, CDRL2, and CDRL3 are the light chain complementarity determining regions written in order from the amino terminal side of the light chain amino acid sequence.

[0017] Thus, the anti-tetranor-PGDM monoclonal antibody or a fragment thereof is preferably (a) a CDRH1 consisting of the amino acid sequence set forth in GYT-Xaa1-T-Xaa2-Y-Xaa3 (SEQ ID NO: 1), where Xaa1 is F, A or S, Xaa2 is N or R, and Xaa3 is A or W; (b) a CDRH2 consisting of the amino acid sequence set forth in I-Xaa4-P-Xaa5-Xaa6-Xaa7-Xaa8-T (SEQ ID NO: 2), where Xaa4 is N or Y, Xaa5 is F or G, Xaa6 is N or D, Xaa7 is D or G, and Xaa8 is G, N, or D; (c) a CDRH3 consisting of the amino acid sequence set forth in A-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-Xaa17-Xaa18-Xaa19-Xaa20 (SEQ ID NO: 3), in which Xaa9 is R, S or T, Xaa10 is Y or V, Xaa11 is Y or absent, Xaa12 is Y or absent, Xaa13 is Y or absent, Xaa14 is G or S, Xaa15 is S or R, Xaa16 is K or W, Xaa17 is A or F, Xaa18 is M or F, Xaa19 is D or A, and Xaa20 is Y or V; and / or (d) a CDRL1 consisting of the amino acid sequence set forth in Xaa21-GAV-Xaa22-Xaa23-S-Xaa24-Xaa25 (SEQ ID NO: 4), in which Xaa21 is T or S, Xaa22 is T or R, Xaa23 is T or I, Xaa24 is N, Y or K, and Xaa25 is Y or H; (e) a CDRL2 consisting of the amino acid sequence set forth in Xaa26-T-Xaa27, where Xaa26 is G or D and Xaa27 is N or D; and (f) a CDRL3 consisting of the amino acid sequence set forth in SEQ ID NO:5: ALW-Xaa28-SNHW-Xaa29, wherein Xaa28 is Y, F or N, and Xaa29 is V or I; The light chain variable region comprises:

[0018] The amino acid sequence of each CDR may have one or several amino acid deletions, substitutions, or additions, so long as the anti-tetranor-PGDM monoclonal antibody or a fragment thereof specifically binds to tetranor-PGDM. As used herein, "several" refers to 2 to 10, preferably 2 to 5, and more preferably 2 or 3, depending on the length of the sequence.

[0019] The substituted amino acid is preferably an amino acid that conserves the properties of the original amino acid side chain as classified below, but the amino acid substitution is not limited to conservative substitution. hydrophobic amino acids (A, I, L, M, F, P, W, Y, V); Hydrophilic amino acids (R, D, N, C, E, Q, G, H, K, S, T); Amino acids with aliphatic side chains (G, A, V, L, I, P); Amino acids with hydroxyl-containing side chains (S, T, Y); Amino acids with sulfur atom-containing side chains (C, M); Amino acids with carboxylic acid and amide-containing side chains (D, N, E, Q); Amino acids with base-containing side chains (R, K, H); Amino acids with aromatic side chains (H, F, Y, W)

[0020] In one embodiment, the amino acid substitution may be an amino acid that exists at the corresponding position in a naturally occurring human antibody.

[0021] In one embodiment, the amino acid substitutions may be outside the complementarity determining regions (CDRs).

[0022] In one embodiment, the amino acid substitutions may be in the heavy chain variable region or the light chain variable region.

[0023] Alternatively, the amino acid sequence of each CDR may be composed of an amino acid sequence having 80% or more homology, preferably 80% or more identity, to the sequence shown in each SEQ ID NO, so long as it specifically binds to tetranor-PGDM. The sequence homology or identity is preferably 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more, more preferably 99% or more.

[0024] In one embodiment, the anti-tetranor-PGDM monoclonal antibody has the following structure: (a) a CDRH1 consisting of the amino acid sequence set forth in GYT-Xaa1-T-Xaa2-Y-Xaa3 (SEQ ID NO: 1), where Xaa1 is F, A or S, Xaa2 is N or R, and Xaa3 is A or W; (b) a CDRH2 consisting of the amino acid sequence set forth in I-Xaa4-P-Xaa5-Xaa6-Xaa7-Xaa8-T (SEQ ID NO: 2), where Xaa4 is N or Y, Xaa5 is F or G, Xaa6 is N or D, Xaa7 is D or G, and Xaa8 is G, N, or D; (c) a CDRH3 consisting of the amino acid sequence set forth in A-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-Xaa17-Xaa18-Xaa19-Xaa20 (SEQ ID NO: 3), in which Xaa9 is R, S or T, Xaa10 is Y or V, Xaa11 is Y or absent, Xaa12 is Y or absent, Xaa13 is Y or absent, Xaa14 is G or S, Xaa15 is S or R, Xaa16 is K or W, Xaa17 is A or F, Xaa18 is M or F, Xaa19 is D or A, and Xaa20 is Y or V; (d) a CDRL1 consisting of the amino acid sequence set forth in Xaa21-GAV-Xaa22-Xaa23-S-Xaa24-Xaa25 (SEQ ID NO: 4), in which Xaa21 is T or S, Xaa22 is T or R, Xaa23 is T or I, Xaa24 is N, Y or K, and Xaa25 is Y or H; (e) a CDRL2 consisting of the amino acid sequence set forth in Xaa26-T-Xaa27, where Xaa26 is G or D and Xaa27 is N or D; and (f) a CDRL3 consisting of the amino acid sequence set forth in SEQ ID NO:5: ALW-Xaa28-SNHW-Xaa29, wherein Xaa28 is Y, F or N, and Xaa29 is V or I; or a variable region comprising at least one CDR selected from the group consisting of At least one variable region containing a CDR consisting of an amino acid sequence having one or several amino acid deletions, substitutions or additions in the amino acid sequence of each CDR; or The antibody or a fragment thereof may contain at least one variable region having a CDR consisting of an amino acid sequence having 80% or more identity with the amino acid sequence of each CDR, and binds to an epitope to which the antibody or fragment thereof binds.

[0025] As used herein, "epitope" refers to a substructure of tetranor-PGDM to which an anti-tetranor-PGDM monoclonal antibody or a fragment thereof binds. Such a substructure includes those having the following chemical formula: [ka] The carbon chain at positions 7 to 11 of tetranor-PGDM, represented by the formula: (1) is considered, particularly the 11-keto group. Positions 7 to 11 are numbered based on the carbon numbering of PGD2, and positions 1 to 4 are missing.

[0026] In one embodiment, the anti-tetranor-PGDM monoclonal antibody has the following structure: (a) a CDRH1 consisting of the amino acid sequence set forth in GYT-Xaa1-T-Xaa2-Y-Xaa3 (SEQ ID NO: 1), where Xaa1 is F, A or S, Xaa2 is N or R, and Xaa3 is A or W; (b) a CDRH2 consisting of the amino acid sequence set forth in I-Xaa4-P-Xaa5-Xaa6-Xaa7-Xaa8-T (SEQ ID NO: 2), where Xaa4 is N or Y, Xaa5 is F or G, Xaa6 is N or D, Xaa7 is D or G, and Xaa8 is G, N, or D; (c) a CDRH3 consisting of the amino acid sequence set forth in A-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-Xaa17-Xaa18-Xaa19-Xaa20 (SEQ ID NO: 3), in which Xaa9 is R, S or T, Xaa10 is Y or V, Xaa11 is Y or absent, Xaa12 is Y or absent, Xaa13 is Y or absent, Xaa14 is G or S, Xaa15 is S or R, Xaa16 is K or W, Xaa17 is A or F, Xaa18 is M or F, Xaa19 is D or A, and Xaa20 is Y or V; or a heavy chain variable region comprising a heavy chain variable region including CDRH1, CDRH2, and CDRH3, each of which has an amino acid sequence having one or several amino acid deletions, substitutions, or additions in the amino acid sequence of each CDR; The antibody or a fragment thereof may comprise a heavy chain variable region including CDRH1, CDRH2, and CDRH3, the amino acid sequences of which have 80% or more identity with the amino acid sequences of each CDR.

[0027] In one embodiment, the heavy chain variable region of the anti-tetranor-PGDM monoclonal antibody or a fragment thereof may comprise at least 109 contiguous amino acids of the amino acid sequence set forth in any one of SEQ ID NOs: 9, 22, 35, 48, 61, and 74.

[0028] As used herein, "at least 109 contiguous amino acids of the amino acid sequence set forth in any one of SEQ ID NOs: 9, 22, 35, 48, 61, and 74" means 109, 110, 112, or more contiguous amino acids in the amino acid sequence set forth in any one of SEQ ID NOs: 9, 22, 35, 48, 61, and 74. Such contiguous amino acids preferably include the amino acid sequences of CDRH1, CDRH2, and CDRH3 described above.

[0029] In one embodiment, the heavy chain variable region of the anti-tetranor-PGDM monoclonal antibody or a fragment thereof may comprise an amino acid sequence set forth in any one of SEQ ID NOs: 9, 22, 35, 48, 61, and 74, an amino acid sequence having one or several amino acid deletions, substitutions, or additions in the amino acid sequence set forth in any one of SEQ ID NOs: 9, 22, 35, 48, 61, and 74, or an amino acid sequence having 80% or more identity to the amino acid sequence set forth in any one of SEQ ID NOs: 9, 22, 35, 48, 61, and 74.

[0030] In one embodiment, the anti-tetranor-PGDM monoclonal antibody has the following structure: (d) a CDRL1 consisting of the amino acid sequence set forth in Xaa21-GAV-Xaa22-Xaa23-S-Xaa24-Xaa25 (SEQ ID NO: 4), in which Xaa21 is T or S, Xaa22 is T or R, Xaa23 is T or I, Xaa24 is N, Y or K, and Xaa25 is Y or H; (e) a CDRL2 consisting of the amino acid sequence set forth in Xaa26-T-Xaa27, where Xaa26 is G or D and Xaa27 is N or D; and (f) a CDRL3 consisting of the amino acid sequence set forth in SEQ ID NO:5: ALW-Xaa28-SNHW-Xaa29, wherein Xaa28 is Y, F or N, and Xaa29 is V or I; or a light chain variable region comprising a light chain variable region including CDRL1, CDRL2, and CDRL3, each of which has an amino acid sequence having one or several amino acid deletions, substitutions, or additions in the amino acid sequence of each CDR; The antibody or fragment thereof may comprise a light chain variable region including CDRL1, CDRL2, and CDRL3, the amino acid sequences of which have 80% or more identity with the amino acid sequences of each CDR.

[0031] In one embodiment, the anti-tetranor-PGDM monoclonal antibody has the following structure: (a) a CDRH1 consisting of the amino acid sequence set forth in GYT-Xaa1-T-Xaa2-Y-Xaa3 (SEQ ID NO: 1), where Xaa1 is F, A or S, Xaa2 is N or R, and Xaa3 is A or W; (b) a CDRH2 consisting of the amino acid sequence set forth in I-Xaa4-P-Xaa5-Xaa6-Xaa7-Xaa8-T (SEQ ID NO: 2), where Xaa4 is N or Y, Xaa5 is F or G, Xaa6 is N or D, Xaa7 is D or G, and Xaa8 is G, N, or D; (c) a CDRH3 consisting of the amino acid sequence set forth in A-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-Xaa17-Xaa18-Xaa19-Xaa20 (SEQ ID NO: 3), in which Xaa9 is R, S or T, Xaa10 is Y or V, Xaa11 is Y or absent, Xaa12 is Y or absent, Xaa13 is Y or absent, Xaa14 is G or S, Xaa15 is S or R, Xaa16 is K or W, Xaa17 is A or F, Xaa18 is M or F, Xaa19 is D or A, and Xaa20 is Y or V; (d) a CDRL1 consisting of the amino acid sequence set forth in Xaa21-GAV-Xaa22-Xaa23-S-Xaa24-Xaa25 (SEQ ID NO: 4), in which Xaa21 is T or S, Xaa22 is T or R, Xaa23 is T or I, Xaa24 is N, Y or K, and Xaa25 is Y or H; (e) a CDRL2 consisting of the amino acid sequence set forth in Xaa26-T-Xaa27, where Xaa26 is G or D and Xaa27 is N or D; and (f) a CDRL3 consisting of the amino acid sequence set forth in SEQ ID NO:5: ALW-Xaa28-SNHW-Xaa29, wherein Xaa28 is Y, F or N, and Xaa29 is V or I; or a variable region including CDRH1, CDRH2, and CDRH3, and CDRL1, CDRL2, and CDRL3, each of which has an amino acid sequence having one or several amino acid deletions, substitutions, or additions in the amino acid sequence of each CDR; or The antibody or a fragment thereof may comprise a variable region including CDRH1, CDRH2, CDRH3, and CDRL1, CDRL2, and CDRL3, each of which has an amino acid sequence having 80% or more identity with the amino acid sequence of each CDR.

[0032] In one embodiment, when Xaa2 in CDRH1 is N, Xaa1 can be F and Xaa3 can be A; or when Xaa2 is R, Xaa1 can be F, A or S.

[0033] Xaa1 is preferably F. Xaa2 is preferably N. Xaa3 is preferably A. CDRH1 in which Xaa1 is F, Xaa2 is N and Xaa3 is A is preferred.

[0034] In one embodiment, when Xaa4 in CDRH2 is N, Xaa5-Xaa6-Xaa7- Xaa8 can be FNDG; alternatively, when Xaa4 is Y, Xaa5-Xaa6-Xaa7 can be GDG and Xaa8 can be N or D.

[0035] Preferably, Xaa4 is N. Preferably, Xaa5-Xaa6-Xaa7-Xaa8 is FNDG. Preferred is a CDRH2 where Xaa4 is N and Xaa5-Xaa6-Xaa7-Xaa8 is FNDG.

[0036] In one embodiment, when Xaa10 in CDRH3 is Y, Xaa9 may be R, Xaa11 may be Y, Xaa12 may be Y, Xaa13 may be Y, Xaa14 may be G, Xaa15 may be S, Xaa16 may be K, Xaa17 may be A, Xaa18 may be M, Xaa19 may be D, and Xaa20 is Y. or when Xaa10 is V, Xaa9 may be S or T, Xaa11 may be absent, Xaa12 may be absent, Xaa13 may be absent, Xaa14 may be S, Xaa15 may be R, Xaa16 may be W, Xaa17 may be F, Xaa18 may be F, Xaa19 may be A, and Xaa20 may be V.

[0037] Xaa9 is preferably R. Xaa10 is preferably Y. Xaa11 is preferably present, particularly Y. Xaa12 is preferably present, particularly Y. Xaa13 is preferably present, particularly Y. Xaa14 is preferably G. Xaa15 is preferably S. Xaa16 is preferably K. Xaa17 is preferably A. Xaa18 is preferably M. Xaa19 is preferably D. Xaa20 is preferably Y. Preferred is a CDRH3 in which Xaa9 is R, Xaa10 is Y, Xaa11 is Y, Xaa12 is Y, Xaa13 is Y, Xaa14 is G, Xaa15 is S, Xaa16 is K, Xaa17 is A, Xaa18 is M, Xaa19 is D, and Xaa20 is Y.

[0038] In one embodiment, when Xaa22 and Xaa23 in CDRL1 are each T, Xaa21 may be T or S, Xaa24 may be N, Y or K, and Xaa25 may be Y or H; or when Xaa22 is R and Xaa23 is I, Xaa21 may be T, Xaa24 may be N, and Xaa25 may be Y.

[0039] Xaa21 is preferably T. Xaa22 is preferably T or R. Xaa23 is preferably T or I. Xaa24 is preferably N. A CDRL1 in which Xaa21 is T, Xaa22 is T or R, Xaa23 is T or I, Xaa24 is N, and Xaa25 is Y is preferred. A CDRL1 in which Xaa21 is T, Xaa22 is R, Xaa23 is I, Xaa24 is N, and Xaa25 is Y is more preferred.

[0040] In one embodiment, when Xaa26 in CDRL2 is G, then Xaa27 may not be D.

[0041] Preferably, Xaa26 is G. Preferably, Xaa27 is N. Preferred is a CDRL2 in which Xaa26 is G and Xaa27 is N.

[0042] In one embodiment, when Xaa28 in CDRL3 is Y, Xaa29 can be V or I; when Xaa28 is F, Xaa29 can be V; or when Xaa28 is N, Xaa29 can be V. CDRL3s in which Xaa28 is Y or N and Xaa29 is V are preferred.

[0043] In one embodiment, the light chain variable region of the anti-tetranor-PGDM monoclonal antibody or a fragment thereof may comprise at least 99 consecutive amino acids of the amino acid sequence set forth in any one of SEQ ID NOs:95 to 99.

[0044] As used herein, "at least 99 contiguous amino acids of the amino acid sequence set forth in any one of SEQ ID NOs: 16, 29, 42, 55, 68, 81" means 99, 100, 101, 102 or more contiguous amino acids in the amino acid sequence set forth in any one of SEQ ID NOs: 16, 29, 42, 55, 68, 81. Such contiguous amino acids preferably include CDRL1, CDRL2 and CDRL3 as described above.

[0045] In one embodiment, the light chain variable region of the anti-tetranor-PGDM monoclonal antibody or a fragment thereof may comprise an amino acid sequence set forth in any one of SEQ ID NOs: 16, 29, 42, 55, 68, and 81, an amino acid sequence having one or several amino acid deletions, substitutions, or additions in the amino acid sequence set forth in any one of SEQ ID NOs: 16, 29, 42, 55, 68, and 81, or an amino acid sequence having 80% or more identity to the amino acid sequence set forth in any one of SEQ ID NOs: 16, 29, 42, 55, 68, and 81.

[0046] As long as the anti-tetranor-PGDM monoclonal antibody has the above-mentioned CDRs, other structures, such as the structures of the variable region and constant region other than the CDRs, are not particularly limited. Examples of amino acid sequences encoding the heavy chain variable region containing the above-mentioned CDRH1, CDRH2, and CDRH3, and the light chain variable region containing CDRL1, CDRL2, and CDRL3, respectively, include the amino acid sequences of SEQ ID NOs: 9, 22, 35, 48, 61, and 74, and the amino acid sequences of SEQ ID NOs: 16, 29, 42, 55, 68, and 81, respectively.

[0047] In a preferred embodiment, the anti-tetranor-PGDM monoclonal antibody or a fragment thereof may comprise a heavy chain variable region having the amino acid sequence of any one of SEQ ID NOs: 9, 22, 35, 48, 61, or 74, and a light chain variable region having the amino acid sequence of any one of SEQ ID NOs: 16, 29, 42, 55, 68, or 81.

[0048] In a preferred embodiment, the humanized anti-tetranor-PGDM monoclonal antibody or fragment thereof may comprise a heavy chain variable region having the amino acid sequence of any one of SEQ ID NOs: 9, 22, 35, 48, 61, or 74, and a light chain variable region having the amino acid sequence of any one of SEQ ID NOs: 16, 29, 42, 55, 68, or 81. (Examples of combinations: SEQ ID NO:9 and SEQ ID NO:16; SEQ ID NO:22 and SEQ ID NO:29; SEQ ID NO:35 and SEQ ID NO:42; SEQ ID NO:48 and SEQ ID NO:55; SEQ ID NO:74 and SEQ ID NO:81)

[0049] As used herein, "antibody" refers to a natural or wholly or partially synthetically produced artificial immunoglobulin or fragment thereof. Antibodies may be of any isotype: IgG, IgM, IgA, IgE, or IgD. There are nine known classes (isotypes) of human immunoglobulins: IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgD, IgE, and IgM.

[0050] The origin of the antibody does not matter, and it may be any mammal, for example, human, or non-human animal such as mouse, rat, guinea pig, hamster, rabbit, goat, sheep, camel, etc. Not only human antibodies, but also recombinant antibodies such as humanized antibodies and chimeric antibodies can be used. As used herein, a "humanized antibody" is an antibody in which the CDR of a human antibody is replaced with a CDR derived from a non-human animal antibody. In addition to the CDR, some framework amino acid residues may be grafted onto the human antibody. When a CDR derived from a non-human animal antibody is used in a human, it is preferable to combine it with the constant region of a human antibody.

[0051] The anti-tetranor-PGDM monoclonal antibody may be chemically or biologically modified as long as the desired effect is achieved. Chemical modifications include the attachment of a chemical moiety to the amino acid backbone, chemical modifications of N- or O-linked carbohydrate chains, etc. Biological modifications may include those that have been post-translationally modified (e.g., glycosylation to the N- or O-linked, processing of the N- or C-terminus, deamidation, isomerization of aspartic acid, oxidation of methionine), those that have been expressed using a prokaryotic host cell to add a methionine residue to the N-terminus, etc.

[0052] The modified form may further be a deletion form in which one or two amino acids are deleted at the carboxyl terminus of the heavy chain, or such a deletion form which is amidated.

[0053] The two heavy chains constituting the anti-tetranor-PGDM monoclonal antibody may be a combination of any one type of heavy chain selected from the group consisting of full-length and the above-mentioned deletion forms, or a combination of any two types of heavy chains.

[0054] As used herein, a "fragment" of an antibody refers to a functional fragment that exhibits at least a part of the function of the antibody before fragmentation, and examples thereof include Fab, F(ab')2, scFv, Fab', single-chain antibody (scFv), etc. The fragment is not limited to these molecules, and may be any fragment as long as it specifically binds to tetranor-PGDM. For example, an anti-tetranor-PGDM monoclonal antibody may be an antibody that has a single heavy chain variable region and does not have a light chain sequence, such as a single domain antibody or nanobody.

[0055] The anti-tetranor-PGDM monoclonal antibody or a fragment thereof may contain a linker depending on the purpose. For example, when multiple variable regions constituting the antigen-binding site of an antibody are linked together, such as in a single-chain antibody, a linker may be interposed between them. For example, a single-chain antibody is obtained by linking a heavy chain variable region and a light chain variable region via a linker. The sequence of the linker can be appropriately determined by those skilled in the art.

[0056] A fragment of an anti-tetranor-PGDM monoclonal antibody can be obtained by treating a full-length molecule of an antibody protein with an enzyme such as papain or pepsin. Alternatively, the fragment may be produced by expressing a gene encoding a desired fragment in a suitable host cell. When transforming a host cell, the heavy chain sequence gene and the light chain sequence gene can be inserted into the same expression vector, or they can be inserted into separate expression vectors. The host cell may be either a prokaryotic cell or a eukaryotic cell. Examples of prokaryotic cells include bacterial cells such as Escherichia coli and Bacillus subtilis. When a eukaryotic cell is used as a host, an animal cell, a plant cell, or a eukaryotic microorganism can be used. An animal cell, a plant cell, or a fungal cell can be used. Examples of animal cells include the following cells. (1) Mammalian cells: CHO, COS, myeloma, BHK, Hela, Vero, HEK293, Ba / F3, HL-60, Jurkat, SK-HEP1, etc. (2) Amphibian cells: Xenopus oocytes, etc. (3) Insect cells: sf9, sf21, Tn5, etc.

[0057] (Polynucleotide) In a second aspect, there is provided a polynucleotide encoding the above-mentioned anti-tetranor-PGDM monoclonal antibody of the present invention or a fragment thereof (polynucleotide of the present invention).

[0058] The polynucleotide of the present invention may be a single-stranded or double-stranded polynucleotide containing a nucleotide sequence encoding the amino acid sequence of an anti-tetranor-PGDM monoclonal antibody or a fragment thereof and / or its complementary strand (DNA including cDNA, etc., or RNA including mRNA, cRNA, etc.).

[0059] The heavy chain variable region (or heavy chain) and the light chain variable region (or light chain) of the anti-tetranor-PGDM monoclonal antibody or a fragment thereof may be encoded on the same polynucleotide, or may be encoded on separate polynucleotides and provided as a combination thereof. The combination of a polynucleotide encoding the heavy chain variable region (or heavy chain) and a polynucleotide encoding the light chain variable region (or light chain) is also encompassed by the term "polynucleotide encoding an anti-tetranor-PGDM monoclonal antibody or a fragment thereof."

[0060] Examples of polynucleotides encoding anti-tetranor-PGDM monoclonal antibodies or fragments thereof include below: (a) a nucleotide sequence encoding CDRH1 consisting of the amino acid sequence set forth in GYT-Xaa1-T-Xaa2-Y-Xaa3 (SEQ ID NO: 1), where Xaa1 is F, A or S, Xaa2 is N or R, and Xaa3 is A or W; (b) a base sequence encoding CDRH2 consisting of the amino acid sequence set forth in I-Xaa4-P-Xaa5-Xaa6-Xaa7-Xaa8-T (SEQ ID NO: 2), where Xaa4 is N or Y, Xaa5 is F or G, Xaa6 is N or D, Xaa7 is D or G, and Xaa8 is G, N, or D; (c) a base sequence encoding a CDRH3 consisting of the amino acid sequence set forth in A-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-Xaa17-Xaa18-Xaa19-Xaa20 (SEQ ID NO: 3), in which Xaa9 is R, S or T, Xaa10 is Y or V, Xaa11 is Y or absent, Xaa12 is Y or absent, Xaa13 is Y or absent, Xaa14 is G or S, Xaa15 is S or R, Xaa16 is K or W, Xaa17 is A or F, Xaa18 is M or F, Xaa19 is D or A, and Xaa20 is Y or V; (d) a base sequence encoding CDRL1 consisting of the amino acid sequence set forth in Xaa21-GAV-Xaa22-Xaa23-S-Xaa24-Xaa25 (SEQ ID NO: 4), where Xaa21 is T or S, Xaa22 is T or R, Xaa23 is T or I, Xaa24 is N, Y or K, and Xaa25 is Y or H; (e) a base sequence encoding a CDRL2 consisting of the amino acid sequence set forth in Xaa26-T-Xaa27, where Xaa26 is G or D and Xaa27 is N or D; and (f) a base sequence encoding a CDRL3 consisting of the amino acid sequence set forth in ALW-Xaa28-SNHW-Xaa29 (SEQ ID NO:5), wherein Xaa28 is Y, F, or N, and Xaa29 is V or I; Examples include those having a base sequence encoding at least one or more CDRs selected from the group consisting of:

[0061] Examples of VH nucleotide sequences containing the nucleotide sequences of (a) to (c) include SEQ ID NOs: 8, 21, 34, 47, 60, and 73. Examples of VL nucleotide sequences containing the nucleotide sequences of (d) to (f) include SEQ ID NOs: 15, 28, 41, 54, 67, and 80. A polynucleotide encoding a gene for an antibody or a fragment thereof may have a nucleotide sequence substantially identical to the nucleotide sequence represented by any of the above SEQ ID NOs. A substantially identical nucleotide sequence refers to a polynucleotide having a sequence that has 80% or more homology, preferably 80% or more identity, to the nucleotide sequence represented by each SEQ ID NO:, for example, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more, preferably 99% or more identity, or a polynucleotide that can hybridize under stringent conditions to a polynucleotide having a sequence complementary to the nucleotide sequence represented by each SEQ ID NO:, and the protein encoded by the polynucleotide has a desired function, for example, one that specifically binds to tetranor-PGDM.

[0062] Here, stringent conditions refer to hybridization conditions that can be easily determined by those skilled in the art, and are generally empirical experimental conditions that depend on the base length of the nucleic acid, washing temperature, and salt concentration. In general, the longer the base, the higher the temperature for proper annealing, and the shorter the base, the lower the temperature. Hybridization generally depends on the ability of complementary strands to reanneal in an environment slightly lower than their melting point.

[0063] In one embodiment, a polynucleotide encoding an anti-tetranor-PGDM monoclonal antibody or a fragment thereof has the following structure: (a) a nucleotide sequence encoding CDRH1 consisting of the amino acid sequence set forth in GYT-Xaa1-T-Xaa2-Y-Xaa3 (SEQ ID NO: 1), where Xaa1 is F, A or S, Xaa2 is N or R, and Xaa3 is A or W; (b) a base sequence encoding CDRH2 consisting of the amino acid sequence set forth in I-Xaa4-P-Xaa5-Xaa6-Xaa7-Xaa8-T (SEQ ID NO: 2), where Xaa4 is N or Y, Xaa5 is F or G, Xaa6 is N or D, Xaa7 is D or G, and Xaa8 is G, N, or D; and (c) a base sequence encoding a CDRH3 consisting of the amino acid sequence set forth in A-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-Xaa17-Xaa18-Xaa19-Xaa20 (SEQ ID NO: 3), in which Xaa9 is R, S or T, Xaa10 is Y or V, Xaa11 is Y or absent, Xaa12 is Y or absent, Xaa13 is Y or absent, Xaa14 is G or S, Xaa15 is S or R, Xaa16 is K or W, Xaa17 is A or F, Xaa18 is M or F, Xaa19 is D or A, and Xaa20 is Y or V; Have or a nucleotide sequence encoding CDRH1, CDRH2, and CDRH3, each of which has one or more base deletions, substitutions, or additions in the nucleotide sequence encoding each CDR; It may have a base sequence encoding CDRH1, CDRH2, and CDRH3, which consists of a base sequence having 80% or more identity to the base sequence encoding each CDR.

[0064] In one embodiment, a polynucleotide encoding an anti-tetranor-PGDM monoclonal antibody or a fragment thereof has the following structure: (d) a base sequence encoding CDRL1 consisting of the amino acid sequence set forth in Xaa21-GAV-Xaa22-Xaa23-S-Xaa24-Xaa25 (SEQ ID NO: 4), where Xaa21 is T or S, Xaa22 is T or R, Xaa23 is T or I, Xaa24 is N, Y or K, and Xaa25 is Y or H; (e) a base sequence encoding a CDRL2 consisting of the amino acid sequence set forth in Xaa26-T-Xaa27, where Xaa26 is G or D and Xaa27 is N or D; and (f) a base sequence encoding a CDRL3 consisting of the amino acid sequence set forth in ALW-Xaa28-SNHW-Xaa29 (SEQ ID NO:5), wherein Xaa28 is Y, F, or N, and Xaa29 is V or I; Have or a nucleotide sequence encoding CDRL1, CDRL2, and CDRL3, each of which has one or more base deletions, substitutions, or additions in the nucleotide sequence encoding each CDR; It may have a base sequence encoding CDRL1, CDRL2, and CDRL3, which are base sequences having 80% or more identity to the base sequence encoding each CDR.

[0065] In one embodiment, the polynucleotide encoding the gene for the anti-tetranor-PGDM monoclonal antibody or a fragment thereof is selected from the group consisting of: (a) a nucleotide sequence encoding CDRH1 consisting of the amino acid sequence set forth in GYT-Xaa1-T-Xaa2-Y-Xaa3 (SEQ ID NO: 1), where Xaa1 is F, A or S, Xaa2 is N or R, and Xaa3 is A or W; (b) a base sequence encoding CDRH2 consisting of the amino acid sequence set forth in I-Xaa4-P-Xaa5-Xaa6-Xaa7-Xaa8-T (SEQ ID NO: 2), where Xaa4 is N or Y, Xaa5 is F or G, Xaa6 is N or D, Xaa7 is D or G, and Xaa8 is G, N, or D; (c) a base sequence encoding a CDRH3 consisting of the amino acid sequence set forth in A-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-Xaa17-Xaa18-Xaa19-Xaa20 (SEQ ID NO: 3), in which Xaa9 is R, S or T, Xaa10 is Y or V, Xaa11 is Y or absent, Xaa12 is Y or absent, Xaa13 is Y or absent, Xaa14 is G or S, Xaa15 is S or R, Xaa16 is K or W, Xaa17 is A or F, Xaa18 is M or F, Xaa19 is D or A, and Xaa20 is Y or V; (d) a base sequence encoding CDRL1 consisting of the amino acid sequence set forth in Xaa21-GAV-Xaa22-Xaa23-S-Xaa24-Xaa25 (SEQ ID NO: 4), where Xaa21 is T or S, Xaa22 is T or R, Xaa23 is T or I, Xaa24 is N, Y or K, and Xaa25 is Y or H; (e) a base sequence encoding a CDRL2 consisting of the amino acid sequence set forth in Xaa26-T-Xaa27, where Xaa26 is G or D and Xaa27 is N or D; and (f) a base sequence encoding a CDRL3 consisting of the amino acid sequence set forth in ALW-Xaa28-SNHW-Xaa29 (SEQ ID NO:5), wherein Xaa28 is Y, F, or N, and Xaa29 is V or I; Contains or or a nucleotide sequence encoding CDRH1, CDRH2, and CDRH3, and CDRL1, CDRL2, and CDRL3, each of which has a deletion, substitution, or addition of one or several nucleotides in the nucleotide sequence encoding each CDR; It may have a base sequence encoding CDRH1, CDRH2 and CDRH3, and CDRL1, CDRL2 and CDRL3, which are composed of base sequences having 80% or more identity to the base sequence encoding each CDR.

[0066] (Vector and host cell) In a third aspect, there is provided an expression vector comprising a polynucleotide encoding an anti-tetranor-PGDM monoclonal antibody or a fragment thereof, and a host cell transfected with the expression vector, the host cell being capable of producing the anti-tetranor-PGDM monoclonal antibody or a fragment thereof.

[0067] The polynucleotide encoding the heavy chain variable region (or heavy chain) of an anti-tetranor-PGDM monoclonal antibody or a fragment thereof and the polynucleotide encoding the light chain variable region (or light chain) of an anti-tetranor-PGDM monoclonal antibody or a fragment thereof may be included in the same expression vector, or may be incorporated into separate expression vectors and provided as a combination thereof. A combination of an expression vector containing a polynucleotide encoding a heavy chain variable region (or heavy chain) (expression vector for a heavy chain variable region (or heavy chain)) and an expression vector containing a polynucleotide encoding a light chain variable region (or light chain) (expression vector for a light chain variable region (or light chain)) is also included in the "expression vector containing a polynucleotide encoding an anti-tetranor-PGDM monoclonal antibody or a fragment thereof."

[0068] An expression vector containing a polynucleotide encoding an anti-tetranor-PGDM monoclonal antibody or a fragment thereof and a host cell transfected with the expression vector can be obtained by a method known to those skilled in the art. For example, a polynucleotide encoding a single-chain anti-tetranor-PGDM monoclonal antibody is incorporated into a vector suitable for its expression, and the vector is then introduced into a host, whereby the anti-tetranor-PGDM monoclonal antibody or a fragment thereof is expressed. The expression vector preferably contains a promoter, a terminator, or the like suitable for the expression of the anti-tetranor-PGDM monoclonal antibody or a fragment thereof in a host cell. The expression vector may further contain other appropriate control sequences, such as an enhancer.

[0069] The vector can be appropriately selected from expression vectors well known to those skilled in the art, taking into consideration the type of host cell, the expression efficiency of the anti-tetranor-PGDM monoclonal antibody or a fragment thereof, and the type of the vector may be a plasmid vector or a viral vector derived from a retrovirus or adenovirus.

[0070] The host cell is not limited as long as it is capable of expressing an anti-tetranor-PGDM monoclonal antibody or a fragment thereof from an expression vector, and may be a prokaryotic cell such as Escherichia coli, a mammalian cell such as CHO, COS, NIH3T3, HEK293, HEK293T, COS-7, an insect cell such as F9, or a eukaryotic cell such as yeast cell. Examples of mammals include primates such as humans and chimpanzees, and rodents such as mice, rats, and hamsters.

[0071] Transfection of an expression vector into a host cell can be carried out using methods well known to those skilled in the art, such as electroporation, calcium phosphate, lipofection, or DEAE-dextran, or methods using commercially available reagents.

[0072] A host cell (transfectant) transfected with an expression vector containing a polynucleotide encoding an anti-tetranor-PGDM monoclonal antibody or a fragment thereof includes: a transfectant containing the expression vector and expressing an anti-tetranor-PGDM monoclonal antibody or a fragment thereof; and A transfectant (stable transfectant) that expresses an anti-tetranor-PGDM monoclonal antibody or a fragment thereof by incorporating a polynucleotide encoding the anti-tetranor-PGDM monoclonal antibody or a fragment thereof into the chromosome of a host cell in an expressible manner is also included. Such a stable transfectant may or may not contain an expression vector containing a polynucleotide encoding the anti-tetranor-PGDM monoclonal antibody or a fragment thereof. The transfectant is preferably a cell derived from a mammal, such as CHO, COS, NIH3T3, HEK293, HEK293T, or COS-7.

[0073] (Hybridoma) In a fourth embodiment, a hybridoma producing an anti-tetranor-PGDM monoclonal antibody is provided.

[0074] Hybridomas producing anti-tetranor-PGDM monoclonal antibodies can be obtained by immunizing an animal with tetranor-PGDM according to a conventional method, and fusing immune cells obtained from the immunized animal with known myeloma cells by a conventional cell fusion method. However, since tetranor-PGDM is a low molecular weight molecule and is also present in the body, antibodies are difficult to produce. Therefore, it is preferable to use mice that do not produce PGD2 and its metabolic product tetranor-PGDM, which have been deficient in genes encoding two types of PGD2 synthesis enzymes, hematopoietic type and lipocalin type, by genetic modification technology, as the immunized animal, and to complex the immunogen tetranor-PGDM with a carrier protein such as keyhole limpet hemocyanin (KLH). Mice that do not produce PGD2 and its metabolic product tetranor-PGDM can be obtained, for example, by substituting cysteine ​​65 with serine in the PGD2 production site present in exon II of L-PGDS using technology such as the CRISPR / Cas system. The 65th cysteine ​​in the amino acid sequence of L-PGDS (SEQ ID NO:84) is the enzymatic active center (J Biol Chem. 2009 14;284(33):22344-52.), and when this is replaced with another amino acid, such as serine, the PGD synthesis enzyme activity is lost and PGD2 production becomes impossible. From such hybridomas, cells that produce anti-tetranor-PGDM monoclonal antibodies are screened. Examples of animals to be immunized include rodents such as mice, rats, hamsters, and rabbits, and mammals such as monkeys.

[0075] (Method for producing anti-tetranor-PGDM monoclonal antibody) In a fifth aspect, there is provided a method for producing an anti-tetranor-PGDM monoclonal antibody or a fragment thereof. The anti-tetranor-PGDM monoclonal antibody or a fragment thereof may be produced by culturing the above-mentioned host cells, transfectants or hybridomas, or by using recombinant DNA technology.

[0076] Examples of antibodies produced as recombinant proteins by recombinant DNA technology include chimeric antibodies, humanized antibodies, and human antibodies. These antibodies can be produced, for example, by culturing host cells transformed with a recombinant vector encoding the antibody or its heavy or light chain. Recombinant antibodies can also be produced using transgenic animals into which a gene encoding the desired antibody has been introduced.

[0077] The culture conditions for the host cells, transfectants, or hybridomas can be appropriately determined by those skilled in the art depending on the type of the desired anti-tetranor-PGDM monoclonal antibody or fragment thereof, and the host cells. The production method may further include a step of recovering the antibody or fragment thereof that specifically binds to tetranor-PGDM from the culture obtained in the culture step.

[0078] The produced antibody or fragment thereof may be subjected to additional steps such as a purification step before recovery. For example, in order to increase purity, it is preferable to carry out salting out, filtration through a filter, clarification using centrifugation, recovery by affinity, intermediate purification by ion exchange, and final purification by gel filtration.

[0079] (Diagnostic agent for tetranor-PGDM-related diseases) In a sixth aspect, various uses of the anti-tetranor-PGDM monoclonal antibody are provided, for example, diagnostic agents for tetranor-PGDM-associated diseases comprising the antibody or a fragment thereof.

[0080] As used herein, "tetranor-PGDM-related disease" refers to food allergy (WO 2016 / 021704, supra; Maeda S, Nakamura T, Harada H, Tachibana Y, Aritake K, Shimosawa T, et al. Prostaglandin D2 metabolite in urine is an index of food allergy. Sci Rep. 2017;7(1):17687. Epub 2017 / 12 / 17. doi: 10.1038 / s41598-017-17798-w. PubMed PMID: 29247205; PubMed Central PMCID: PMCPMC5732293.; Inagaki S, Maeda S, Narita M, Nakamura T, Shimosawa T, Murata T, et al. Urinary PGDM, a prostaglandin D2 metabolite, is a novel Biomarker for objectively detecting allergic reactions of food allergy. J Allergy Clin Immunol. 2018;142(5):1634-6.e10. Epub 2018 / 07 / 10. doi: 10.1016 / j.jaci.2018.06.032. PubMed PMID: 29981807.), anaphylactic reactions, and muscular dystrophies such as Duchenne muscular dystrophy (Takeshita E, Komaki H, Tachimori H, Miyoshi K, Yamamiya I, Shimizu-Motohashi Y, et al. Urinary prostaglandin metabolites as Duchenne muscular dystrophy progression markers. Brain Dev. 2018;40(10):918-25. Epub 2018 / 07 / 15. doi: 10.1016 / j.braindev.2018.06.012. PubMed PMID: 30006121.), and aspirin-intolerant asthma (Higashi et al., " Urinary tetranor-PGDM concentrations in aspirin-intolerant asthma and anaphylaxis ", J Allergy Clin Immunol. 2012 Feb;129(2):557-9, 559.e1-2. doi: 10.1016 / j.jaci.2011.09.019. Epub 2011 Oct 22.), etc., refer to diseases for which tetranor-PGDM is a diagnostic marker.

[0081] (Kit containing anti-tetranor-PGDM monoclonal antibody) In a seventh aspect, a kit comprising an anti-tetranor-PGDM monoclonal antibody or a fragment thereof is provided.

[0082] The kit is intended to be used for measuring tetranor-PGDM, for example, for a qualitative or quantitative test. A preferred method for measuring tetranor-PGDM is, for example, an immunoassay that utilizes an antigen-antibody reaction with tetranor-PGDM in a sample.

[0083] The immunoassay uses a detectably labeled anti-tetranor-PGDM monoclonal antibody or an antibody (secondary antibody) against the detectably labeled anti-tetranor-PGDM monoclonal antibody. Depending on the labeling method of the antibody, it is classified into enzyme immunoassay (EIA or ELISA), radioimmunoassay (RIA), fluorescent immunoassay (FIA), fluorescent polarization immunoassay (FPIA), chemiluminescence immunoassay (CLIA), etc., and any of these can be suitably used in the kit. The above measurement methods are merely examples, and the above antibodies can also be used in other methods known to those skilled in the art, such as agglutination, chemiluminescence immunoassay (CLIA), electrochemiluminescence immunoassay (ECLIA), etc.

[0084] In the ELISA method, enzymes such as peroxidase and alkaline phosphatase are used, and in the RIA method, 125 I, 131 I, 35 S, 3 In the FPIA method, antibodies labeled with radioactive substances such as H, fluorescent substances such as fluorescein isothiocyanate, rhodamine, dansyl chloride, phycoerythrin, tetramethylrhodamine isothiocyanate, and near-infrared fluorescent materials are used, and in the CLIA method, antibodies labeled with luminescent substances such as luciferase, luciferin, and aequorin are used. In addition, antibodies labeled with nanoparticles such as gold colloids and quantum dots can also be detected.

[0085] In addition, in immunoassays, anti-tetranor-PGDM monoclonal antibodies can be labeled with biotin and then bound to avidin or streptavidin labeled with an enzyme or the like for detection.

[0086] Among immunoassays, the ELISA method using enzyme labeling can measure antigens easily and quickly. There are two types of ELISA: competitive and sandwich. In the competitive method, anti-tetranor-PGDM monoclonal antibodies are fixed to a solid phase carrier such as a microplate, and a urine sample and enzyme-labeled tetranor-PGDM are added to cause an antigen-antibody reaction. After washing, the sample reacts with the enzyme substrate to develop color, and the absorbance is measured. If there is a lot of tetranor-PGDM in the urine sample, the color will be weak, and if there is little tetranor-PGDM in the urine sample, the color will be strong, so the amount of tetranor-PGDM can be calculated using a calibration curve.

[0087] In the sandwich method, anti-tetranor-PGDM monoclonal antibody is immobilized on a solid support, a urine sample is added, and after the reaction, another anti-tetranor-PGDM monoclonal antibody labeled with an enzyme is added and reacted. After washing, the amount of tetranor-PGDM can be determined by reacting with an enzyme substrate, developing color, and measuring absorbance. In the sandwich method, after the antibody immobilized on the solid support reacts with tetranor-PGDM in the urine sample, an unlabeled anti-tetranor-PGDM monoclonal antibody (primary antibody) is added, and an antibody against this unlabeled anti-tetranor-PGDM body (secondary antibody) may be added after being enzyme-labeled.

[0088] When the enzyme is peroxidase, 3,3'-diaminobenzidine (DAB), 3,3',5,5'-tetramethylbenzidine (TMB), o-phenylenediamine (OPD), etc. can be used as the enzyme substrate, and when the enzyme is alkaline phosphatase, p-nitrophenyl phosphate (NPP), etc. can be used.

[0089] As used herein, the term "solid phase carrier" is not particularly limited as long as it is a carrier capable of immobilizing an antibody, and examples of such carriers include glass, metal, and resin microtiter plates, substrates, beads, nitrocellulose membranes, nylon membranes, and PVDF membranes. Target substances and antibodies can be immobilized on these solid phase carriers according to known methods.

[0090] The form of the kit is not limited, but it is preferable that the kit is a stick-shaped kit containing an anti-tetranor-PGDM monoclonal antibody, and that the amount of tetranor-PGDM in the sample can be visualized by a colored line or the like. Such a stick-shaped kit can be a known one. For example, a stick using immunochromatography is known, and it can be configured such that an antibody storage section in which a first anti-tetranor-PGDM monoclonal antibody labeled with gold colloid or the like is stored is stored, and a determination section in which a second anti-tetranor-PGDM monoclonal antibody that recognizes another epitope of tetranor-PGDM is immobilized in a line shape on a cellulose membrane or the like is connected by a thin groove. When a sample is added to such a stick, the labeled antibody and tetranor-PGDM bind to each other in the antibody storage section to form a tetranor-PGDM-labeled antibody complex, and the complex moves through the groove to the determination section by capillary action. When the complex is captured by the immobilized second anti-tetranor-PGDM monoclonal antibody, a red line appears in the determination section due to the plasmon effect of the gold colloid.

[0091] The test stick may have a control line immobilized with an antibody against the labeled antibody. The control line will develop color regardless of the presence or absence of tetranor-PGDM, allowing confirmation of whether the test was performed correctly.

[0092] The stick may further comprise absorbent paper for absorbing the urine sample, a desiccant, etc.

[0093] The stick also stores labeled anti-tetranor-PGEM antibodies in the antibody storage section, and by fixing anti-tetranor-PGEM antibodies that recognize a different epitope of tetranor-PGEM in a line in the measurement section, tetranor-PGDM and tetranor-PGEM can be measured simultaneously.

[0094] Using such a stick, it is possible to easily measure the amount of tetranor-PGDM at home and evaluate the risk and severity of developing food allergy.

[0095] The kit can be used not only for the diagnosis of tetranor-PGDM-related diseases, such as food allergy or Duchenne muscular dystrophy, but also for the evaluation of mast cell activation in food allergy.

[0096] (Detection method for tetranor-PGDM) In an eighth aspect, a method for detecting tetranor-PGDM using an anti-tetranor-PGDM monoclonal antibody or a fragment thereof is provided.

[0097] The method for detecting tetranor-PGDM can be used not only for diagnosing food allergies or Duchenne muscular dystrophy, but also for evaluating mast cell activation due to food allergies.

[0098] (Methods for diagnosing food allergies) In a ninth aspect, there is provided a method for diagnosing food allergy using an anti-tetranor-PGDM monoclonal antibody or a fragment thereof.

[0099] The amount of urinary tetranor-PGDM increases with the severity of food allergy symptoms and the number and activation of mast cells in tissues, and decreases with the suppression of symptoms by the administration of food allergy treatments. Therefore, by measuring the amount of urinary tetranor-PGDM, it is possible to evaluate not only whether a subject has a food allergy, but also the severity of the allergy. In addition, the concentration of tetranor-PGDM in the urine of subjects with food allergies may be high even without antigen stimulation. Therefore, the risk of developing a food allergy can also be evaluated by measuring the amount of urinary tetranor-PGDM in subjects who do not have a food allergy.

[0100] Such an evaluation method includes the steps of detecting the amount of tetranor-PGDM in urine; The method may further include a step of assisting in the determination that the greater the amount of tetranor-PGDM in the urine, the more severe or has become severe the symptoms of food allergy, or the greater or has become the risk of developing the symptoms. The threshold used in such a determination may vary depending on factors such as the age of the subject. Thus, without intending to be limiting, a urinary tetranor-PGDM concentration may be 1.5±0.3 ng / mg creatinine (Cre) in a healthy person, whereas a urinary tetranor-PGDM concentration in a subject with a severe or has become severe symptoms of food allergy, or with a greater or has become the risk of developing the symptoms, may be 2.25 ng / mg Cre or greater.

[0101] In this specification, "food allergy" refers to various allergic reactions that occur when allergens contained in food are taken into the body. Well-known food allergies include allergies to chicken eggs, milk, crustaceans, wheat, fruits, nuts, seafood, and buckwheat, but also allergies caused by other allergens. Symptoms occur in the skin, mucous membranes, digestive system, and respiratory system, and typical symptoms include diarrhea, vomiting, and dermatitis.

[0102] In this specification, a "subject" may refer to a person who may have a food allergy, a person who has actually developed a food allergy, a person who is receiving treatment for a food allergy, a person who is taking a drug for a food allergy, a person who is unknown as to whether or not he or she has a food allergy, etc. Furthermore, a "subject" is not limited to a human being, but may also be a mammal such as a mouse, rat, rabbit, cat, dog, monkey, pig, sheep, cow, or horse.

[0103] In one embodiment of the food allergy testing method according to the present invention, when the amount of tetranor-PGDM in urine is higher, it is determined that the symptoms are more severe or the risk of onset is higher. Whether the amount of tetranor-PGDM in urine is higher may be determined by measuring the amount of tetranor-PGDM in urine collected multiple times from the same individual and comparing the results. In this case, it is possible to evaluate the change in the severity or risk of onset in the same individual. In addition, whether the amount of tetranor-PGDM in urine is higher may be determined by measuring the amount of tetranor-PGDM in urine collected from multiple individuals and comparing the results. In this case, it is possible to evaluate whether the severity or risk of onset is higher than that of other individuals.

[0104] In one embodiment of the food allergy testing method of the present invention, when the amount of tetranor-PGDM in urine is higher than a predetermined value, the symptoms are judged to be severe or the risk of developing a high level, and when it is lower than the predetermined value, the symptoms are judged to be mild or the risk of developing a low level. The predetermined value (cutoff value) can be determined by a conventional method by comparing the amounts of tetranor-PGDM in urine samples from multiple healthy subjects or non-food allergy patients with the amounts of tetranor-PGDM in urine samples from multiple food allergy patients.

[0105] In one embodiment, the food allergy testing method according to the present invention is used to evaluate a therapeutic agent administered to a patient with food allergy or a treatment method performed on the patient. For example, the amount of tetranor-PGDM is measured in a urine sample collected at any time point before or after the start of treatment, and if the amount of tetranor-PGDM decreases, the therapeutic agent or treatment method is judged to be effective, and if the amount of tetranor-PGDM does not decrease or increase, the therapeutic agent or treatment method is judged to be ineffective. In this case, the decrease or increase in the amount of tetranor-PGDM does not have to be a significant decrease or increase, and may be to the extent that a person skilled in the art can judge that there is a tendency for a decrease or increase.

[0106] In one embodiment, the method for testing food allergies according to the present invention may be used to evaluate the efficacy of a drug for the development of a therapeutic agent for food allergies in animal experiments.

[0107] In one embodiment, the method for testing food allergies according to the present invention means examining a sample collected from a subject to obtain information necessary for diagnosis. Such a testing method is carried out, for example, by a testing company or the like.

[0108] The urine used in the test of the present invention may be collected according to a conventional method. It may be a single urine sample or two or more urine samples. The collected urine may be stored at room temperature or at -40°C or lower, for example -80°C, until the time of the test. Frozen urine may be quickly thawed before use in the measurement.

[0109] In addition to the amount of tetranor-PGDM in the subject's urine, the amount of tetranor-PGEM (9,15-dioxo-11α-hydroxy-13,14-dihydro-2,3,4,5-tetranor-prostan-1,20-dioic acid), a metabolic product of PGE2, may also be measured.

[0110] The amount of tetranor-PGDM in urine behaves differently in other inflammatory diseases than in food allergies. Therefore, by measuring the amount of tetranor-PGDM in urine, it is possible to differentiate other inflammatory diseases (e.g., enteritis, asthma, allergic dermatitis). Furthermore, the amount of tetranor-PGEM in urine also behaves differently in other inflammatory diseases than in food allergies. Therefore, by measuring both the amount of tetranor-PGDM and the amount of tetranor-PEGM in urine, it is possible to differentiate similar diseases with higher accuracy.

[0111] More specifically, if the amount of tetranor-PGDM in urine is elevated and maintained for a certain period of time, and the amount of tetranor-PGEM in urine is elevated transiently and then immediately decreased, it can be determined that there is a food allergy. Here, the period of time refers to, for example, 3 days or more, 5 days or more, 7 days or more, 10 days or more, or 20 days or more after the ingestion of a substance that causes food allergy. The term "elevated transiently and then immediately decreased" refers to, for example, the increase followed by a decrease within 5 days, 4 days, or 3 days after the increase.

[0112] The amount of tetranor-PGEM in urine can be measured by a known method, for example, using a mass spectrometer.

[0113] By using anti-tetranor-PGDM monoclonal antibody or a fragment thereof, mast cell activation in food allergy can also be evaluated.

[0114] As used herein, "activation of mast cells" refers to an increase in the number of mast cells or an increase in their activity, including degranulation. As shown in the Examples below, the amount of urinary tetranor-PGDM increases with an increase in mast cells, but does not increase under degranulation inhibition. In addition, the amount of urinary tetranor-PGEM also increases with an increase in mast cells. Therefore, the amount of urinary tetranor-PGDM and the amount of urinary tetranor-PGEM can be used as indicators to evaluate mast cell activation.

[0115] For example, it is known that allergic rhinitis develops in mast cell-deficient mice, whereas food allergies show almost no symptoms in mast cell-deficient mice, and that food allergies are highly mast cell-dependent, with an increase in the number and activity of mast cells being important for their onset and progression. Until now, the only method available for detecting the activation of mast cells (especially gastrointestinal mucosa-type mast cells) specific to food allergies was to measure the histamine concentration in the blood, but because histamine in the blood disappears within 15 minutes, there was virtually no method for detecting mast cell activation.

[0116] (Treatment method for tetranor-PGDM-related diseases) In a tenth aspect, a method of treating a subject diagnosed with an anti-tetranor-PGDM related disorder is provided.

[0117] Subjects diagnosed with tetranor-PGDM-related diseases by the above diagnostic method are given appropriate necessary treatment. For example, known treatments such as hyposensitization therapy can be applied to subjects diagnosed with food allergies.

[0118] Desensitization therapy is a method of inducing immune tolerance by administering diluted allergens to patients under the supervision of a doctor. While most treatments for allergic diseases are symptomatic, desensitization therapy has attracted attention because it aims to cure the disease by affecting the mechanism of action of the disease. Desensitization therapy starts with an extremely low dosage and gradually increases the dosage, but in this case, a method is required to appropriately evaluate the severity of the patient's allergic symptoms so as not to cause severe symptoms by administering an amount of allergen that exceeds the threshold.

[0119] There are no particular limitations on the administration route, dosage, and administration frequency of the hyposensitization therapy, and these can be appropriately selected depending on various conditions such as the age, weight, symptoms, etc. Examples of the administration route include intradermal, subcutaneous, intramuscular, intraperitoneal, transdermal, transmucosal, oral, inhalation, and other routes of administration to an individual.

[0120] The present invention will be described in more detail below with reference to examples, but the present invention is not limited to these examples. EXAMPLES

[0121] Materials and Methods mouse Using the offset nicking method that applies the CRISPR / Cas system, we generated L-PGDS C65S mutant mice in which the cysteine ​​at position 65 of L-PGDS (sequence number 84) was replaced with serine. Specifically, exon-3 of L-PGDS in the target embryonic stem cell was used as a targeting vector, and after cleavage using Cas9 nickase and guide RNA, vector DNA was inserted to convert TGC (cysteine) to AGC (serine). L-PGDS C65S mutant mice were obtained by microinjecting these cells into 8-cell embryos of ICR strain mice.

[0122] Preparation of monoclonal antibodies L-PGDS C65S mice were immunized subcutaneously with tetranor-PGDM conjugated to keyhole limpet hemocyanin (KLH). Spleen cells from immunized mice were fused with myeloma cells (SP2 / 0-Ag14) using standard protocols [6]. Positive hybridomas were cloned by limiting dilution. IgG antibodies were purified from serum-free medium of hybridoma culture supernatants.

[0123] Determination of the cDNA sequence of the variable regions of each antibody Isolation of gene sequences encoding VH and VL of anti-tetranor-PGDM monoclonal antibody Hybridomas producing each antibody: 1x10 6 Total RNA was prepared from each sample using TRI Reagent (Molecular Research Center, Inc., Cat#TR118).

[0124] Cloning of VH and VL genes of anti-tetranor-PGDM monoclonal antibody: cDNA was prepared from 1 μg of total RNA of each hybridoma using SMARTer (registered trademark) Mouse BCR IgG H / K / L Profiling Kit (Clontech, Cat# 634422). The isotype of the obtained antibody was identified using Iso-Gold Rapid Mouse Monoclonal Antibody Isotyping κ&λ Kit (BioAssay Works, Cat# KSOT03-010). Using the obtained cDNA as a template, the VH and VL cDNA sequences were determined using a combination of BCR Primer 1V (containing a forward primer) included in the kit and the reverse primer of mBCR Primer 1H (encoding the mouse IgG heavy chain constant region), mBCR Primer 1L (κ) or mBCR Primer 1L (λ) (encoding the mouse IgG light chain constant region).

[0125] Specifically, PCR was performed using a combination of BCR Primer 1V and mBCR Primer 1H to amplify the VH cDNA fragment of each antibody. PCR was also performed using a combination of mouse Ig(κ)-specific primer (mBCR Primer 1L(κ)) and BCR Primer 1V, or a combination of mouse Ig(λ)-specific primer (mBCR Primer 1L(λ)) and BCR Primer 1V to amplify the VL cDNA fragment of each antibody.

[0126] PCR was performed 35 times with a reaction cycle consisting of 98°C for 10 seconds, 60°C for 15 seconds, and 68°C for 45 seconds.

[0127] Each PCR amplified product was purified using a FastGene Gel / PCR Extraction kit (Nippon Genetics, Cat#FG-91202).

[0128] dA was added to the 3' end of the obtained gene fragment using TArget CloneTM-Plus- (TOYOBO, Cat#TAK-201), and the fragment was inserted into the pTA2 Vector provided with the kit.

[0129] The obtained plasmid was introduced into Escherichia coli DH5α strain. Plasmids were extracted from the obtained transformants using FastGene Plasmid Mini Kit (Nihon Genetics, Cat#FG-90502) and the nucleotide sequences were analyzed. As a result, it was confirmed that full-length VH cDNA and VL cDNA, each of which had an ATG sequence presumed to be the initiation codon at the 5' end of the cDNA, were obtained.

[0130] Competitive enzyme immunoassay The reactivity of tetranor-PGDM monoclonal antibody was examined by competitive EIA. Various concentrations of tetranor-PGDM monoclonal antibody were incubated for 1 h on a 96-well plate immobilized with anti-mouse goat IgG antibody (Cayman Chemical, Michigan, USA). The plate was then washed three times with phosphate-buffered saline (PBS-T) containing 0.5% bovine serum albumin (BSA) and 0.05% (v / v) Tween-20 (PBS-T). Subsequently, tetranor-PGDM-bound acetylcholinesterase tracer (Tracer) was incubated overnight. The plate was then washed three times with PBS-T and incubated with Ellman's reagent for 1 h. The absorbance at 405 nm was measured using a microplate reader (Perkin Elmer, Massachusetts, USA). The selectivity of tetranor-PGDM for prostaglandin metabolites was examined by competitive EIA using tetranor-PGEM, tetranor-PGAM, and tetranor-PGFM.

[0131] The results are shown below. [Table 1]

[0132] Establishment of EIA law The effects of pH (5.0, 6.0, 6.5, 7.0, 7.5, 8.0, and 9.0) and ionic strength (NaCl content in 10 mM phosphate buffer) on the performance of the EIA were investigated. Under each condition, the standard inhibition curve of tetranor-PGDM was plotted. The cross-reactivity was calculated based on the following formula: Cross-reactivity (%) = (IC of tetranor-PGDM 50 / Other tetranor-PGM ICs 50 ) x 100.

[0133] Reproducibility test Tetranor-PGDM of known concentration was added to the assay solution and measured. The within-run reproducibility was calculated from nine measurements, and the daily reproducibility was calculated by performing measurements over three days.

[0134] Accuracy prediction Analyte concentration and absorbance data sets were fitted with the following four-parameter logistic equation with fitting parameters a, b, c, and d: [7, 8] f(X)=(a - d) / (1 +(X / c) b )+d Based on the model proposed by Hayashi et al. [9], the relative standard deviation (RSD) of the entire analysis (ρT) is expressed as follows: ρT 2 = X 2 / (X + G) 2 ×(ρX 2 +ρG 2 )+ρB 2 +ρS 2 +(σW / f(X)×100) 2 [9] In this equation, G is the amount of labeled antigen, ρX, ρG, ρB, and ρS are the RSDs of the pipette volumes of analyte labeled antigen, antibody, and substrate, respectively, and ρS was two-thirds the RSD of the pipette volume of chromogen-substrate solution. σW is the SD of the specific absorbance between wells of the plate. Since the concentration of labeled antigen is unknown, the approximate equation for the uncertainty of a competitive EIA is ρT 2 =ρB 2 +(σW / f(X)×100) 2 [9] was used. ρB = 0.782116 and σW = 0.0026. ρT was calculated from blank subtracted measurements. ρB values ​​were calculated by weighing 20 aliquots of liquid with a pipette and calculating the RSD. σW values ​​were calculated from the well-to-well SD of absorbance in blank wells (n = 96).

[0135] Measurement of tetranor-PGDM in artificial urine Tetranor-PGDM dissolved in distilled water was added to artificial urine (Table 2) to prepare urine samples of four different concentrations (1.25, 2.5, 5.0, and 10.0 ng / mL). [Table 2]

[0136] For solid-phase extraction (SPE), 0.4 mL of urine sample was diluted to 0.8 mL with 0.1% (v / v) formic acid. This was applied to an SPE cartridge column (HLB μElution plate, Waters, MA, USA) pretreated with 200 μL of acetonitrile and distilled water. After washing the column with 200 μL of distilled water and 200 μL of hexane, the lipid fraction was eluted with 50 μL of acetonitrile. The eluate was collected and dried in vacuum, and the resulting residue was redissolved in 0.4 mL of assay solution. The sample solution containing tetranor-PGDM was then subjected to EIA. At the same time, tetranor-PGDM was measured by LC-MS / MS [2, 3]. The recovery rate from SPE determined by LC-MS / MS was 77.1% (Table 3). [Table 3]

[0137] result Competitive EIA optimization Hybridomas producing monoclonal antibodies (Mab) against tetranor-PGDM were obtained from spleen cells of immunized mice. 60-141Mab was then purified and applied to competitive enzyme immunoassay (ELISA).

[0138] Because patient urine samples have different physicochemical properties, the optimal ionic strength and pH for the Mab-based EIA were investigated. As shown in Figure 1A, a NaCl concentration of 600 mM strongly interfered with the competition curve. The IC50 values ​​were 6.6, 5.7, 5.3, and 7.3 ng / mL at NaCl concentrations of 15, 75, 150, and 300 mM in the assay buffer, respectively. Therefore, the optimal salt concentration was set at 150 mM NaCl in phosphate buffer. To determine the optimal pH of the assay buffer, the IC50 values ​​at pH 5.0, 6.0, 6.5, 7.0, 7.5, 8.0, and 9.0 were 8.6, 6.6, 5.5, 5.6, 4.8, 5.2, and 4.8 ng / mL, respectively (Figure 1B). These results indicated that the assay system was more sensitive under neutral to slightly alkaline conditions than under slightly acidic conditions. Therefore, the optimal pH was set at pH 7.5.

[0139] Under the optimized conditions, the competition curve for tetranor-PGDM showed an IC50 value of 1.79 ± 0.36 (Figure 1C).

[0140] EIA Verification Tetranor-PGDM was serially diluted in the assay solution to determine the detection limit of tetranor-PGDM. The limit of detection (LOD) was 0.0498 ng / mL, and the range of quantification (ROQ) values ​​were 0.252–20.2 ng / mL. The LOD and ROQ were defined as the concentration of 30% RSD and the concentration region of <10% RSD, respectively (Figure 1D).

[0141] The imprecision of this EIA was evaluated using an assay solution containing tetranor-PGDM at three different concentrations. The intra- and inter-experimental CVs were 3.9%–6.0% (n = 9) and 5.7%–10.4% (n = 9), respectively (Table 4). [Table 4]

[0142] The recoveries of tetranor-PGDM were between 89.4% and 111.7%. All recoveries and coefficients of variation of tetranor-PGDM were within acceptable ranges.

[0143] Cross-reactivity of generated Mabs against tetranor-PGDM In addition to tetranor-PGDM, other urinary PG metabolites such as tetranor-PGEM and tetranor-PGFM exist in urine (Figure 2). Next, cross-reactivity to tetranor-PGEM, tetranor-PGAM, and tetranor-PGFM was evaluated. The cross-reactivity with tetranor-PGEM, tetranor-PGFM, and tetranor-PGAM was 0.00%, 0.00%, and 1.17%, respectively (Table 5). [Table 5] The established EIA method showed no significant cross-reactivity with these metabolites, suggesting that this EIA method can measure urinary tetranor-PGDM with sufficient specificity.

[0144] Measurement of tetranor-PGDM in artificial urine A known amount of tetranor-PGDM was added to artificial urine, and the recovery of tetranor-PGDM was measured by competitive EIA using 60-141 MAb.

[0145] The dilution linearity is an indicator of the validity of the EIA method using anti-tetranor-PGDM monoclonal antibody. First, an artificial urine sample containing 20 ng / mL of tetranor-PGDM was serially diluted, and the tetranor-PGDM recovery rate by the antibody was measured. The measured value of tetranor-PGDM did not have a linear correlation with the dilution ratio. Furthermore, the recovery rate of tetranor-PGDM was less than 30.2% (Figure 3A). These results suggest that some urinary components may cause negative interference in the EIA method.

[0146] Therefore, to eliminate the negative interference, urine samples were subjected to solid phase extraction (SPE). The recovery rate of tetranor-PGDM from SPE determined by LC-MS / MS was 77.1% (Table 2). After SPE, an artificial urine sample containing 13.9 ng / mL of tetranor-PGDM was serially diluted and measured. After SPE, the measured value of the artificial urine showed good linearity with the dilution factor (r = 0.999, Figure 3B).

[0147] Different concentrations of tetranor-PGDM were added to artificial urine to determine the recovery rate. The recovery rates of tetranor-PGDM ranged from 82.3% to 113.5%. All of the recoveries of tetranor-PGDM were within the acceptable range (Table 6). [Table 6] The concentrations of tetranor-PGDM were 0.85 (AU-1) and 5.95 (AU-2).

[0148] Consideration In this study, anti-tetranor-PGDM monoclonal antibodies were prepared and a highly sensitive competitive EIA method was established for the measurement of tetranor-PGDM. High average recoveries (89.4%-111.7%) with coefficients of variation of 3.9%-10.4% were obtained in the assay solution samples. The ROQs of the EIA for the measurement of tetranor-PGDM were 0.252-196 20.2 ng / mL. The matrix effect of the samples was eliminated by the use of SPE. High average recoveries (82.3%-113.5%) were obtained in the urine samples after SPE.

[0149] Antigen-antibody binding is characterized by weak intermolecular bonds, so changes in either ionic strength or pH can affect this interaction. The individual characteristics of each urine sample can affect the reliability of the analysis using EIA methods

[10] . Up to pH 9.0, the IC of EIA 50 The values ​​did not change significantly. Increasing the ionic strength to 300 mM did not significantly change the recognition of tetranor-PGDM. These results suggest that changes in either ionic strength or pH have little effect on the EIA method using the 60-141 antibody.

[0150] In healthy individuals, the urinary tetranor-PGDM concentration is 1.5 ± 0.3 ng / mg creatinine (Cre) [1]. The urinary Cre concentration is approximately 1 mg / mL

[11] . We previously demonstrated that the optimal cutoff value of urinary tetranor-PGDM for oral challenge testing in food allergy patients was 2.25 ng / mg Cre [3]. The LOQ value was lower than the cutoff value. In another disease, the urinary tetranor-PGDM concentration of Duchenne muscular dystrophy patients was reported to be 9.7 ng / mg Cre [4]. These results indicated that this optimized EIA method is acceptable for the detection of urinary tetranor-PGDM in patients with food allergy or Duchenne muscular dystrophy.

[0151] The urinary concentrations of tetranor-PGEM and tetranor-PGFM were 8–15 ng / mg Cre and 11–59 ng / mL, respectively [12, 13]. This competitive EIA method showed negligible cross-reactivity with other tetranor-PG metabolites. Mice were immunized with KLH-conjugated tetranor-PGDM, which was prepared by conjugating KLH to the carboxyl group of tetranor-PGDM via NHS / EDC-mediated esterification. It is generally believed that antibodies best recognize the portion of a hapten that is furthest from the conjugated bond. Thus, the epitope of the 60-141 antibody is thought to be located on the cyclopentane ring of tetranor-PGDM. Furthermore, the 60-141 antibody did not recognize tetranor-PGEM, tetranor-PGFM, or tetranor-PGAM, which do not have an 11-keto group.

[0152] This suggests that the epitope of the 60-141 antibody is located at the 11-keto group of tetranor-PGDM. In other words, the cross-reactivity test showed that the 60-141 antibody is almost exclusively directed against the tetranor-PGDM structure.

[0153] Furthermore, the 60-141 antibody showed sufficiently high specificity for PGDM compared to other lipids, with 0.631% for tetranor-PGEM, 3.876% for tetranor-PGAM, and <0.003% for tetranor-PGFM.

[0154] In this study, we successfully generated one monoclonal antibody and developed a highly sensitive competitive EIA method, which will be useful for quantifying tetranor-PGDM in biological fluids, evaluating animal disease models, as a diagnostic indicator, and for treatment monitoring of food allergies and other diseases.

[0155] Reference materials 1. Song WL, Wang M, Ricciotti E, Fries S, Yu Y, Grosser T, et al. Tetranor PGDM, an abundant urinary metabolite reflects biosynthesis of prostaglandin D2 in mice and humans. J Biol Chem. 2008;283(2):1179-88. Epub 2007 / 11 / 13. doi: 10.1074 / jbc.M706839200. PubMed PMID : 17993463 . 2. Maeda S, Nakamura T, Harada H, Tachibana Y, Aritake K, Shimosawa T, et al. Prostaglandin D2 metabolite in urine is an index of food allergy. Sci Rep. 2017;7(1):17687. Epub 2017 / 12 / 17. doi: 10.1038 / s41598-017-17798-w. PubMed PMID: 29247205; PubMed Central PMCID: PMCPMC5732293. 3. Inagaki S, Maeda S, Narita M, Nakamura T, Shimosawa T, Murata T, et al. Urinary PGDM, a prostaglandin D2 metabolite, is a novel biomarker for objectively detecting allergic reactions of food allergy. J Allergy Clin Immunol. 2018;142(5):1634–6.e10. Epub 2018 / 07 / 1 doi: 10.1016 / j.jaci.2018.06.032. PubMed PMID : 29981807 . 4. Takeshita E, Komaki H, Tachimori H, Miyoshi K, Yamamiya I, Shimizu-Motohashi Y, et al. Urinary prostaglandin metabolites as Duchenne muscular dystrophy progression markers. Brain Dev. 2018;40(10):918-25. Epub 2018 / 07 / 15. doi: 10.1016 / j.braindev.2018.06.012. PubMed PMID: 30006121. 5. Higashi N, Mita H, Yamaguchi H, Fukutomi Y, Akiyama K, Taniguchi M. Urinary tetranor-PGDM concentrations in aspirin-intolerant asthma and anaphylaxis. J Allergy Clin Immunol. 2012;129(2):557-9, 9.e1-2. Epub 2011 / 10 / 25. doi: 10.1016 / j.jaci.2011.09.019. PubMed PMID: 22018904. 6. Harlow E, Lane D. Antibodies : a laboratory manual: Cold Spring Harbor Laboratory; 1988. xiii, 726 p. p. 7. Queffelec AL, Boisde F, Larue JP, Haelters JP, Corbel B, Thouvenot D, et al. Development of an immunoassay (ELISA) for the quantification of thiram in lettuce. J Agric Food Chem. 2001;49(4):1675-80. Epub 2001 / 04 / 20. doi: 10.1021 / jf000937j. PubMed PMID: 11308309. 8. Dudley RA, Edwards P, Ekins RP, Finney DJ, McKenzie IG, Raab GM, et al. Guidelines for immunoassay data processing. Clin Chem. 1985;31(8):1264-71. Epub 1985 / 08 / 01. PubMed PMID: 3893796. 9. Hayashi Y, Matsuda R, Maitani T, Imai K, Nishimura W, Ito K, et al. Precision, limit of detection and range of quantitation in competitive ELISA. Anal Chem. 2004;76(5):1295-301. Epub 2004 / 02 / 28. doi: 10.1021 / ac0302859. PubMed PMID: 14987084. 10. Schneider D, Gee S, Kreissig S, Harris A, Kramer P, Marco M, et al. New frontiers in agrochemical immunoassay. AOAC International, Washington DC. 1995:103-21. 11. Smith-Palmer T. Separation methods applicable to urinary creatine and creatinine. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;781(1-2):93-106. Epub 2002 / 11 / 27. doi: 10.1016 / s1570-0232(02)00617-7. PubMed PMID: 12450655. 12. Granstrom E, Samuelsson B. On the metabolism of prostaglandin F 2 in female subjects. II. Structures of six metabolites. J Biol Chem. 1971;246(24):7470-85. Epub 1971 / 12 / 25. PubMed PMID: 5135312. 13. Zhang Y, Zhang G, Clarke PA, Huang JT, Takahashi E, Muirhead D, et al. Simultaneous and high-throughput quantitation of urinary tetranor PGDM and tetranor PGEM by online SPE-LC-MS / MS as inflammatory biomarkers. J Mass Spectrom. 2011;46(7):705-11. Epub 2011 / 06 / 28. doi: 10.1002 / jms.1941. PubMed PMID: 21706677. [Sequence List Free Text]

[0156] SEQ ID NO: 1: Amino acid sequence of CDRH1: GYT-Xaa1-T-Xaa2-Y-Xaa3 (wherein Xaa1 is F or A, Xaa2 is N or R, and Xaa3 is A or W) SEQ ID NO:2: Amino acid sequence of CDRH2: I-Xaa4-P-Xaa5-Xaa6-Xaa7-Xaa8-T (wherein Xaa4 is N or Y, Xaa5 is F or G, Xaa6 is N or D, Xaa7 is D or G, and Xaa8 is G, N, or D). SEQ ID NO:3: Amino acid sequence of CDRH3: A-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-Xaa17-Xaa18-Xaa19-Xaa20 (wherein Xaa9 is R, S or T, Xaa10 is Y or V, Xaa11 is Y or absent, Xaa12 is Y or absent, Xaa13 is Y or absent, Xaa14 is G or S, Xaa15 is S or R, Xaa16 is K or W, Xaa17 is A or F, Xaa18 is M or F, Xaa19 is D or A, and Xaa20 is Y or V). SEQ ID NO: 4: Amino acid sequence of CDRL1: Xaa21-GAV-Xaa22-Xaa23-S-Xaa24-Xaa25 (wherein Xaa21 is T or S, Xaa22 is T or R, Xaa23 is T or I, Xaa24 is N, Y or K, and Xaa25 is Y or H). SEQ ID NO:5: Amino acid sequence of CDRL3: ALW-Xaa28-SNHW-Xaa29 (wherein Xaa28 is Y, F or N and Xaa29 is V or I) SEQ ID NO: 6: Full base sequence of VH of 31-13 antibody (including signal sequence) SEQ ID NO: 7: 31-13 antibody VH complete amino acid sequence (including signal sequence) SEQ ID NO: 8: VH base sequence of 31-13 antibody (excluding signal sequence) SEQ ID NO:9: VH amino acid sequence of 31-13 antibody (excluding signal sequence) SEQ ID NO:10: CDRH1 amino acid sequence of 31-13 antibody SEQ ID NO:11: CDRH2 amino acid sequence of the 31-13 antibody SEQ ID NO:12: CDRH3 amino acid sequence of 31-13 antibody SEQ ID NO: 13: 31-13 antibody VL complete base sequence (including signal sequence) SEQ ID NO: 14: 31-13 antibody VL complete amino acid sequence (including signal sequence) SEQ ID NO: 15: VL base sequence of 31-13 antibody (excluding signal sequence) SEQ ID NO: 16: 31-13 antibody VL amino acid sequence (excluding signal sequence) SEQ ID NO: 17: CDRL1 amino acid sequence of the 31-13 antibody SEQ ID NO:18: CDRL3 amino acid sequence of 31-13 antibody SEQ ID NO: 19: 44-63 antibody VH complete base sequence (including signal sequence) SEQ ID NO: 20: 44-63 antibody VH complete amino acid sequence (including signal sequence) SEQ ID NO: 21: VH base sequence of 44-63 antibody (excluding signal sequence) SEQ ID NO: 22: VH amino acid sequence of 44-63 antibody (excluding signal sequence) SEQ ID NO: 23: CDRH1 amino acid sequence of antibody 44-63 SEQ ID NO:24:44-63 CDRH2 amino acid sequence of antibody SEQ ID NO:25: CDRH3 amino acid sequence of 44-63 antibody SEQ ID NO: 26: 44-63 antibody VL complete base sequence (including signal sequence) SEQ ID NO: 27: 44-63 antibody VL full amino acid sequence (including signal sequence) SEQ ID NO: 28: VL base sequence of 44-63 antibody (excluding signal sequence) SEQ ID NO: 29: 44-63 VL amino acid sequence of antibody (excluding signal sequence) SEQ ID NO:30:44-63 CDRL1 amino acid sequence of antibody SEQ ID NO:31: CDRL3 amino acid sequence of 44-63 antibody SEQ ID NO: 32: Full base sequence of VH of 47-11 antibody (including signal sequence) SEQ ID NO: 33: 47-11 antibody VH complete amino acid sequence (including signal sequence) SEQ ID NO: 34: VH base sequence of 47-11 antibody (excluding signal sequence) SEQ ID NO: 35: VH amino acid sequence of 47-11 antibody (excluding signal sequence) SEQ ID NO: 36: CDRH1 amino acid sequence of 47-11 antibody SEQ ID NO: 37: CDRH2 amino acid sequence of 47-11 antibody SEQ ID NO:38: CDRH3 amino acid sequence of 47-11 antibody SEQ ID NO: 39: 47-11 antibody VL complete base sequence (including signal sequence) SEQ ID NO: 40: 47-11 antibody VL full amino acid sequence (including signal sequence) SEQ ID NO: 41: VL base sequence of 47-11 antibody (excluding signal sequence) SEQ ID NO: 42: VL amino acid sequence of 47-11 antibody (excluding signal sequence) SEQ ID NO: 43: CDRL1 amino acid sequence of 47-11 antibody SEQ ID NO: 44: CDRL3 amino acid sequence of 47-11 antibody SEQ ID NO: 45: 50-32 antibody VH complete base sequence (including signal sequence) SEQ ID NO: 46: 50-32 antibody VH complete amino acid sequence (including signal sequence) SEQ ID NO: 47: VH base sequence of 50-32 antibody (excluding signal sequence) SEQ ID NO: 48: 50-32 VH amino acid sequence of antibody (excluding signal sequence) SEQ ID NO: 49: CDRH1 amino acid sequence of the 50-32 antibody SEQ ID NO:50:50-32 antibody CDRH2 amino acid sequence SEQ ID NO:51: CDRH3 amino acid sequence of the 50-32 antibody SEQ ID NO: 52: 50-32 antibody VL complete base sequence (including signal sequence) SEQ ID NO:53: 50-32 antibody VL complete amino acid sequence (including signal sequence) SEQ ID NO: 54: VL base sequence of 50-32 antibody (excluding signal sequence) SEQ ID NO: 55: VL amino acid sequence of 50-32 antibody (excluding signal sequence) SEQ ID NO:56: CDRL1 amino acid sequence of the 50-32 antibody SEQ ID NO:57: CDRL3 amino acid sequence of the 50-32 antibody SEQ ID NO: 58: 53-113 antibody VH complete base sequence (including signal sequence) SEQ ID NO: 59: 53-113 antibody VH full amino acid sequence (including signal sequence) SEQ ID NO: 60: VH base sequence of 53-113 antibody (excluding signal sequence) SEQ ID NO: 61: VH amino acid sequence of 53-113 antibody (excluding signal sequence) SEQ ID NO:62:53-113 CDRH1 amino acid sequence of antibody SEQ ID NO: 63:53-113 CDRH2 amino acid sequence of antibody SEQ ID NO:64:53-113 CDRH3 amino acid sequence of antibody SEQ ID NO: 65: 53-113 antibody VL complete base sequence (including signal sequence) SEQ ID NO: 66: 53-113 antibody VL full amino acid sequence (including signal sequence) SEQ ID NO: 67: VL base sequence of 53-113 antibody (excluding signal sequence) SEQ ID NO: 68: 53-113 VL amino acid sequence of antibody (excluding signal sequence) SEQ ID NO: 69:53-113 CDRL1 amino acid sequence of antibody SEQ ID NO: 70:53-113 CDRL3 amino acid sequence of antibody SEQ ID NO: 71: 60-141 antibody VH complete base sequence (including signal sequence) SEQ ID NO: 72: 60-141 antibody VH full amino acid sequence (including signal sequence) SEQ ID NO: 73: VH base sequence of 60-141 antibody (excluding signal sequence) SEQ ID NO: 74: VH amino acid sequence of antibody 60-141 (excluding signal sequence) SEQ ID NO: 75:60-141 CDRH1 amino acid sequence of antibody SEQ ID NO: 76:60-141 CDRH2 amino acid sequence of antibody SEQ ID NO: 77:60-141 CDRH3 amino acid sequence of antibody SEQ ID NO: 78: 60-141 antibody VL complete base sequence (including signal sequence) SEQ ID NO: 79: 60-141 The complete VL amino acid sequence of the antibody (including the signal sequence) SEQ ID NO: 80: VL base sequence of 60-141 antibody (excluding signal sequence) SEQ ID NO: 81: VL amino acid sequence of antibody 60-141 (excluding signal sequence) SEQ ID NO: 82:60-141 CDRL1 amino acid sequence of antibody SEQ ID NO: 83:60-141 CDRL3 amino acid sequence of antibody

Claims

1. A monoclonal antibody or a fragment thereof that specifically binds to tetranor-PGDM, below: (a) a CDRH1 consisting of the amino acid sequence set forth in GYT-Xaa1-T-Xaa2-Y-Xaa3 (SEQ ID NO: 1), where Xaa1 is F, Xaa2 is N, and Xaa3 is A; (b) a CDRH2 consisting of the amino acid sequence set forth in I-Xaa4-P-Xaa5-Xaa6-Xaa7-Xaa8-T (SEQ ID NO:2), where Xaa4 is N, Xaa5 is F, Xaa6 is N, Xaa7 is D, and Xaa8 is G; (c) a CDRH3 consisting of the amino acid sequence set forth in A-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-Xaa17-Xaa18-Xaa19-Xaa20 (SEQ ID NO: 3), in which Xaa9 is R, Xaa10 is Y, Xaa11 is Y, Xaa12 is Y, Xaa13 is Y, Xaa14 is G, Xaa15 is S, Xaa16 is K, Xaa17 is A, Xaa18 is M, Xaa19 is D, and Xaa20 is Y; (d) a CDRL1 consisting of the amino acid sequence set forth in Xaa21-GAV-Xaa22-Xaa23-S-Xaa24-Xaa25 (SEQ ID NO:4), wherein Xaa21 is T, Xaa22 is R, Xaa23 is I, Xaa24 is N, and Xaa25 is Y; (e) a CDRL2 consisting of the amino acid sequence set forth in Xaa26-T-Xaa27, where Xaa26 is G and Xaa27 is N; and (f) a CDRL3 consisting of the amino acid sequence set forth in SEQ ID NO:5: ALW-Xaa28-SNHW-Xaa29, wherein Xaa28 is N and Xaa29 is V; A monoclonal antibody or a fragment thereof comprising:

2. The monoclonal antibody or fragment thereof of claim 1, which does not substantially bind to tetranor-PGEM, tetranor-PGFM, or tetranor-PGAM.

3. The monoclonal antibody or fragment thereof according to claim 1 or 2, which recognizes the carbon chains at positions 7 to 11 of tetranor-PGDM.

4. The monoclonal antibody or fragment thereof according to any one of claims 1 to 3, wherein the constant region is of human origin.

5. The monoclonal antibody or fragment thereof according to any one of claims 1 to 4, which is human chimeric or humanized.

6. The monoclonal antibody or fragment thereof according to any one of claims 1 to 5, which is selected from the group consisting of Fab, F(ab')2, Fab', Fv and single chain antibodies.

7. A polynucleotide encoding the monoclonal antibody or a fragment thereof according to any one of claims 1 to 6.

8. An expression vector comprising the polynucleotide of claim 7.

9. A host cell transfected with the expression vector of claim 8.

10. The host cell of claim 9 , which is a eukaryotic cell.

11. A hybridoma producing the monoclonal antibody according to any one of claims 1 to 6.

12. A diagnostic agent for a tetranor-PGDM-related disease, comprising the monoclonal antibody or a fragment thereof according to any one of claims 1 to 6.

13. The diagnostic agent according to claim 12, wherein the tetranor-PGDM-related disease is food allergy, anaphylactic reaction, muscular dystrophy, or aspirin-intolerant asthma.

14. A kit comprising the monoclonal antibody or a fragment thereof according to any one of claims 1 to 6, or the diagnostic agent according to claim 12 or 13.

15. The kit of claim 14, further comprising a solid phase carrier, on which the monoclonal antibody or fragment thereof is immobilized.

16. A method for detecting tetranor-PGDM in vitro, using the monoclonal antibody or fragment thereof according to any one of claims 1 to 6, or the diagnostic agent according to claim 12 or 13.

17. 1. A method for assisting a subject in determining whether or not they have a food allergy, comprising: A step of detecting the amount of tetranor-PGDM in urine in vitro using the monoclonal antibody or fragment thereof according to any one of claims 1 to 6, or the diagnostic agent according to claim 12 or 13; A method comprising a step of assisting in determining that the higher the amount of tetranor-PGDM in the urine, the more severe or has become the symptoms of food allergy, or the higher or has become the risk of developing a food allergy.

18. The method of claim 17, further comprising a step of measuring the amount of tetranor-PGEM in urine in vitro.

Citation Information

Patent Citations

  • Tetranor-PGDM / PGJM specific immunogens, antibodies, tracers, assay kits and methods for making same

    US20120021437A1

  • Tetranor PGDM: a biomarker of PGD2 synthesis in vivo

    WO2009043015A1

  • Method for detecting muscle degenerative diseases, and method for determining therapeutic efficacy on the diseases

    WO2010104025A1

  • Method and kit for testing for food allergy

    WO2016021704A1